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Diabetes is characterized by development of specific microvascular 
complications and by a high incidence of accelerated atherosclerosis. 
The assumption underlying current clinical treatment is that lowering the level 
of time-averaged glucose concentration, measured as hemoglobin A1c (HbA1c), 
prevents the development and progression of microvascular complications. This 
current treatment recommendation, adopted by diabetes professional societies 
around the world, is based on data from the 1993 Diabetes Control and 
Complications Trial (DCCT). 
Recent Diabetes Control and Complications Trial data analyses show that 
89% of the variation in microvascular complications risk in type 1 diabetes is not 
captured by HbA1c values (time-averaged glucose concentration). Recent 
experimental evidence from Dr Brownlee’s lab, shows that transient exposure to 
threshold levels of high glucose reprograms human endothelial cells to continue 
overproducing reactive oxygen species in the presence of physiologic glucose 
concentrations. This persistent ROS overproduction causes an equally persistent 
overexpression of pro-inflammatory genes in normal glucose due to hystone 
modifications in the proximal promoter of the NF-κB subunit p65. 
Since in normal cells the epigenetic changes are rapidly reversed by histone 
demethylases and histone methyltransferases my thesis work aimed to understand 
how transient exposure to high glucose reprograms endothelial cells, and 
characterize the critical regulatory networks that shift vascular endothelial cells to a 
state of persistent excess ROS production after transient exposure to high glucose.  
We found that transient spikes of hyperglycemia cause persistent 
mitochondrial overproduction of ROS during subsequent periods of prolonged 
normal glucose, causing persistent activation of the epigenetic changes and 
resultant vascular inflammatory gene expression. We identified a multi-component 
positive feedback loop induced by transient exposure to high glucose in human 
vascular endothelial cells which maintains persistently increased ROS production in 
normal glucose, thus we verified that transient disruption of any of the elements in 
the feed back loop rapidly restores the system to its normal state, including 
reversing persistent increased ROS production, persistent hyperglycemia-induced 
epigenetic changes and persistent increased NF-κB-dependent pro-inflammatory 
gene expression. 
Our results highlight the dramatic and long-lasting effects that short-term 
hyperglycemic spikes can have on vascular cells and suggest that transient spikes 
of hyperglycemia may be an HbA1c–independent risk factor for diabetic 
complications. Moreover we understood the mechanism underlying the continue 
overproducing of reactive oxygen species in the presence of physiologic glucose 
concentrations in human endothelial cells. This knowledge will provide the basis for 
developing new type 1 diabetes treatment paradigms that more effectively prevent 
the development and progression of microvascular complications. 
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Diabetes mellitus (DM) refers to a group of common metabolic disorders 
characterized by hyperglycemia. The metabolic dysregulation associated with DM 
causes secondary pathophysiologic changes in multiple organ systems, leading to 
end-stage renal disease (ESRD), non-traumatic lower extremity amputations, and 
adult blindness. It also predisposes to cardiovascular diseases. 
The assumption underlying current clinical treatment is that lowering the level of 
time-averaged glucose concentration, measured as hemoglobin A1c (HbA1c), 
prevents the development and progression of microvascular complications. This 
current treatment recommendation, adopted by diabetes professional societies 
around the world, is based on data from the 1993 Diabetes Control and 
Complications Trial (DCCT), where intensive therapy reduced the risk of sustained 
retinopathy progression by 73% compared with standard treatment. After the 
announcement of the DCCT results, many patients who had been in standard 
therapy group adopted more intensive therapeutic regiments, and their level of 
glycemic control improved. The post-DCCT HbA1c values for both groups have 
become nearly identical during the approximate 10 years of follow-up in the 
Epidemiology of Diabetes Interventions and Complications Study (EDIC). 
Surprisingly, the effects of 6.5-years difference in HbA1c, during the DCCT on the 
incidence if retinopathy and nephropathy, have persisted. People in standard 
treatment group continued to have a higher incidence of microvascular 
complications even with an improvement in glycemic control during the EDIC. 
HbA1c and duration of diabetes (glycemic exposure) explained only about 11% of 
the variation in retinopathy risk for the entire study population, suggesting that the 
remaining 89% of the variation in risk is presumably explained by other factors not 
captured by measurement of HbA1c. 
What factors not captured by HbA1c measurements might explain the remaining 
89% of microvascular complications risk for people with type 1 diabetes? Since 
HbA1c represents the time-averaged mean level of glycemia, it provides no 
information about how closely the fluctuations of blood glucose levels around that 
mean mimic the normal narrow range of blood glucose excursion, and patients with 
identical HbA1c values differ significantly in amplitude and duration of glycemic 
spikes.  
Oxidative stress plays a pivotal role in the development of diabetes vascular 
and neurologic complications. High intracellular concentrations of glucose cause 
increased superoxide production from the mitochondria. This increased superoxide 
production causes the activation of the five major pathways implicated in the 
pathogenesis of complications over the past 40 years: polyol pathway flux, 
increased formation of AGEs (advanced glycation end products), increased 
expression of the receptor for AGEs, (RAGE) and its activating ligands, activation 
of protein kinase C isoforms, and overactivity of the hexosamine pathway. Through 
these pathways, increased intracellular reactive oxygen species (ROS) cause 
defective angiogenesis in response to ischemia and activate a number of 
proinflammatory pathways as demonstrated by overexpression of superoxide 
dismutase in transgenic diabetic mice that prevents diabetic retinopathy, 
nephropathy, and cardiomyopathy.  




Experimental evidence both in cultured primary human endothelial cells and in non-
diabetic mice shows that short exposure to hyperglycemia (6-16 hr) triggers 
persistent increases in proinflammatory gene expression during long subsequent 
periods of normal glycemia (6 days) by inducing persistent epigenetic changes in 
the proximal promoter of NF-κB p65,  
 
increasing p65 expression. This in turn causes persistent increased expression of 
the proinflammatory proteins monocyte chemotactic protein-1, vascular cell 
adhesion molecule-1, intercellular adhesion molecule-1, interleukin-6, and inducible 
nitric oxide synthase. 
These persistent changes in gene expression are induced by spikes of 
hyperglycemia that have durations too short (6-16 hours followed by 6 days of 
normal glycemia) to influence HbA1C values. Since regulation of gene expression 
by methylation of histone lysines is rapidly reversible by the action of demethlases 
and histone methyltransferases, however, the mechanism responsible for the 
persistence of these epigenetic changes has remained puzzling. 
The ability of hyperglycemia to elicit epigenetic changes may be associated with 
diabetes complications. Further exploration into epigenetic mechanisms can yield 
new insights into the pathogenesis of diabetes and its complications and uncover 
potential therapeutic targets and treatment options to prevent the continued 
development of diabetic complications even after glucose control has been 
achieved. 
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The existing paradigm for treatment of type 1 diabetes is to lower hemoglobin 
A1c values, based on the assumption that hemoglobin A1c explains a large 
proportion of microvascular complication risk. However, recent analysis of the 
Diabetes Control and Complications Trial data shows that 89% of the variation in 
retinopathy risk in type 1 diabetes is not captured by HbA1c values (time-averaged 
glucose concentration).  
Transient exposure to threshold levels of high glucose reprograms human 
endothelial cells to continue overproducing reactive oxygen species in the presence 
of physiologic glucose concentrations for many days. This persistent ROS 
overproduction causes an equally persistent overexpression of pro-inflammatory 
genes in normal glucose. The specific aims of this thesis are to identity and 
characterize critical regulatory networks that shift vascular endothelial cells to a 
state of persistent excess ROS production after transient exposure to high glucose. 
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Diabetes mellitus (DM) refers to a group of common metabolic disorders 
characterized by hyperglycemia. Depending on the etiology of the DM, factors 
contributing to hyperglycemia include reduced insulin secretion, decreased glucose 
utilization, and increased glucose production. The metabolic dysregulation 
associated with DM causes secondary pathophysiologic changes in multiple organ 
systems, leading to end-stage renal disease (ESRD), nontraumatic lower extremity 




DM is classified on the basis of the pathogenic process that leads to 
hyperglycemia, as opposed to earlier criteria such as age of onset or type of 
therapy. The two broad categories of DM are designated type 1 and type 2. Type 1 
DM is the result of complete or near-total insulin deficiency. Type 2 DM is a 
heterogeneous group of disorders characterized by variable degrees of insulin 
resistance, impaired insulin secretion, and increased glucose production and is 
preceded by a period of abnormal glucose homeostasis classified as impaired 





























Table 1 Etiologic Classification of Diabetes Mellitus 
I. Type 1 diabetes (beta cell destruction, usually leading to absolute insulin 
deficiency) 
    A. Immune-mediated 
    B. Idiopathic 
II. Type 2 diabetes (may range from predominantly insulin resistance with 
relative insulin deficiency to a predominantly insulin secretory defect with 
insulin resistance) 
III. Other specific types of diabetes 
 A. Genetic defects of beta cell function characterized by mutations in: 
        1. Hepatocyte nuclear transcription factor (HNF) 4  (MODY 1) 
        2. Glucokinase (MODY 2) 
        3. HNF-1α (MODY 3) 
        4. Insulin promoter factor-1 (IPF-1; MODY 4) 
        5. HNF-1β (MODY 5) 
        6. NeuroD1 (MODY 6) 
        7. Mitochondrial DNA 
        8. Subunits of ATP-sensitive potassium channel 
        9. Proinsulin or insulin 
         
B. Genetic defects in insulin action 
        1. Type A insulin resistance 
        2. Leprechaunism 
        3. Rabson-Mendenhall syndrome 
        4. Lipodystrophy syndromes 
 
C. Diseases of the exocrine pancreas—pancreatitis, pancreatectomy, 
neoplasia, cystic fibrosis, hemochromatosis, fibrocalculous pancreatopathy, 
mutations in carboxyl ester lipase 
 
D. Endocrinopathies—acromegaly, Cushing's syndrome, glucagonoma, 
pheochromocytoma, hyperthyroidism, somatostatinoma, aldosteronoma 
E. Drug- or chemical-induced—glucocorticoids, vacor (a rodenticide), 
pentamidine, nicotinic acid, diazoxide, β-adrenergic agonists, thiazides, 
hydantoins, asparaginase, α-interferon, protease inhibitors, antipsychotics 
(atypicals and others), epinephrine 
F. Infections—congenital rubella, cytomegalovirus, coxsackievirus 
G. Uncommon forms of immune-mediated diabetes— "stiff-person" syndrome, 
anti-insulin receptor antibodies 
H. Other genetic syndromes sometimes associated with diabetes— Wolfram's 
syndrome, Down's syndrome, Klinefelter's syndrome, Turner's syndrome, 
Friedreich's ataxia, Huntington's chorea, Laurence-Moon-Biedl syndrome, 
myotonic dystrophy, porphyria, Prader-Willi syndrome 
  
IV. Gestational diabetes mellitus (GDM) 
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Two features of the current classification of DM diverge from previous 
classifications. First, the terms insulin-dependent diabetes mellitus (IDDM) and 
non-insulin-dependent diabetes mellitus (NIDDM) are obsolete. Since many 
individuals with type 2 DM eventually require insulin treatment for control of 
glycemia, the use of the term NIDDM generated considerable confusion. A second 
difference is that age is not a criterion in the classification system. Although type 1 
DM most commonly develops before the age of 30, an autoimmune beta cell 
destructive process can develop at any age. It is estimated that between 5 and 
10% of individuals who develop DM after age 30 years have type 1 DM. Although 
type 2 DM more typically develops with increasing age, it is now being diagnosed 
more frequently in children and young adults, particularly in obese adolescents 




The worldwide prevalence of DM increased dramatically over the past 20 
years, from ~ 30 million cases in 1985 to about 285 million in 2010. Approximately 
1.6 million individuals (>20 years) were newly diagnosed with diabetes in 2010. 
Based on current trends, the International Diabetes Federation expects that 438 
million individuals will have diabetes by the year 2030. Among type 1 and type 2 
DM, the prevalence of type 2 DM is rising much more rapidly, presumably because 
of increasing obesity and the aging of the population. DM increases with aging. In 
2010, the prevalence of DM in the United Sates was estimated to be 0.2% in 
individuals aged <20 years and 11.3% in individuals aged >20 years. In individuals 
aged >65 years, the prevalence of DM was 26.9%. The prevalence is similar in 
men and women throughout most age ranges (11.8% and 10.8%, respectively, in 
individuals aged >20 years). Worldwide estimates project that in 2030 the greatest 
number of individuals with diabetes will be aged 45–64 years (Harrison's Principles 





























Insulin is produced in the beta cells of the pancreatic islets. It is initially 
synthesized as a single-chain 86-aminoacid precursor polypeptide, known as 
preproinsulin. Subsequent proteolytic processing removes the N-terminal signal 
peptide, generating proinsulin. Proinsulin is structurally related to insulin-like growth 
factors I and II, which bind weakly to the insulin receptor. Cleavage of an internal 
31-residue fragment from proinsulin generates the C peptide and the A (21 amino 
acids) and B (30 amino acids) chains of insulin, which are connected by disulfide 
bonds. The mature insulin molecule and C peptide are stored together and co-
secreted from secretory granules in the beta cells. Because C peptide is cleared 
more slowly than insulin, it is a useful marker of insulin secretion and allows 
discrimination of endogenous and exogenous sources of insulin in the evaluation of 
hypoglycemia. Pancreatic beta cells co-secrete islet amyloid polypeptide (IAPP) or 
amylin, a 37-amino-acid peptide, along with insulin. The role of IAPP in normal 
physiology is not fully defined, but it is the major component of the amyloid fibrils 
found in the islets of patients with 2 DM, and an analogue is sometimes used in 
treating type 1 and type 2 DM. Human insulin is produced by recombinant DNA 
technology; structural alterations at one or more amino acid residues modify its 




Glucose is the key regulator of insulin secretion by the pancreatic beta cell, 
although several other molecules (e.g. amino acids, ketones, various nutrients, 
gastrointestinal peptides, and neurotransmitters) also influence insulin secretion. 
Glucose levels >3.9 mmol/L (70 mg/dL) stimulate insulin synthesis, primarily by 
enhancing protein translation and processing. Glucose stimulation of insulin 
secretion begins with its transport into the beta cell by a facilitative glucose 
transporter (Fig.1.1). Glucose phosphorylation by glucokinase is the rate-limiting 
step that controls glucose-regulated insulin secretion. Further metabolism of 
glucose-6-phosphate via glycolysis generates ATP, which inhibits the activity of an 
ATP-sensitive K+ channel. This channel consists of two separate proteins: one is 
the binding site for certain oral hypoglycemics (e.g., sulfonyl-ureas, meglitinides); 
the other is an inwardly rectifying K+ channel protein. Inhibition of this K+ channel 
induces beta cell membrane depolarization, which opens voltage-dependent 
calcium channels (leading to an influx of calcium), and stimulates insulin secretion. 
Insulin secretory profiles reveal a pulsatile pattern of hormone release, with small 
secretory bursts occurring about every 10 min, superimposed upon greater 
amplitude oscillations of about 80–150 min. Incretins are released from 
neuroendocrine cells of the gastrointestinal tract following food ingestion and 
amplify glucose-stimulated insulin secretion and suppress glucagon secretion. 
Glucagon-like peptide 1 (GLP-1), the most potent incretin, is released from L cells 
in the small intestine and stimulates insulin secretion only when the blood glucose 
is above the fasting level. Incretin analogues, are used to enhance endogenous 
insulin secretion. 
CHAPTER 1                                                                                  Diabetes Mellitus 
__________________________________________________________________ 
	  
	   11	  
 
 
Figure 1.1 Mechanisms of glucose-stimulated insulin secretion and abnormalities in diabetes. 
Glucose and other nutrients regulate insulin secretion by the pancreatic beta cell. Glucose is transported 
by a glucose transporter (GLUT1 in humans, GLUT2 in rodents); subsequent glucose metabolism by the 
beta cell alters ion channel activity, leading to insulin secretion. The SUR receptor is the binding site for 
some drugs that act as insulin secretagogues. SUR, sulfonylurea receptor; ATP, adenosine 
triphosphate; ADP, adenosine diphosphate, cAMP, cyclic adenosine monophosphate. IAPP, islet 




Once insulin is secreted into the portal venous system, ~50% is removed and 
degraded by the liver. Unextracted insulin enters the systemic circulation where it 
binds to receptors in target sites. Insulin binding to its receptor stimulates intrinsic 
tyrosine kinase activity, leading to receptor autophosphorylation and the 
recruitment of intracellular signaling molecules, such as insulin receptor substrates 
(IRS) (Fig.1.2). IRS and other adaptor proteins initiate a complex cascade of 
phosphorylation and dephosphorylation reactions, resulting in the widespread 
metabolic and mitogenic effects of insulin. As an example, activation of the 
phosphatidylinositol-3′-kinase (PI-3-kinase) pathway stimulates translocation of a 
facilitative glucose transporter (e.g., GLUT4) to the cell surface, an event that is 
crucial for glucose uptake by skeletal muscle and fat. Activation of other insulin 
receptor signaling pathways induces glycogen synthesis, protein synthesis, 
lipogenesis, and regulation of various genes in insulin-responsive cells. 
Glucose homeostasis reflects a balance between hepatic glucose production 
and peripheral glucose uptake and utilization. Insulin is the most important 
regulator of this metabolic equilibrium, but neural input, metabolic signals, and 
other hormones (e.g.,glucagon) result in integrated control of glucose supply and 
utilization. In the fasting state, low insulin levels increase glucose production by 
promoting hepatic gluconeogenesis and glycogenolysis and reduce glucose uptake 
in insulin-sensitive tissues (skeletal muscle and fat), thereby promoting mobilization 




of stored precursors such as amino acids and free fatty acids (lipolysis). Glucagon, 
secreted by pancreatic alpha cells when blood glucose or insulin levels are low, 
stimulates glycogenolysis and gluconeogenesis by the liver and renal medulla. 
Postprandially, the glucose load elicits a rise in insulin and fall in glucagon, leading 
to a reversal of these processes. Insulin, an anabolic hormone, promotes the 
storage of carbohydrate and fat and protein synthesis. The major portion of 
postprandial glucose is utilized by skeletal muscle, an effect of insulin-stimulated 
glucose uptake. Other tissues, most notably the brain, utilize glucose in an insulin-




Figure 1.2 Insulin signal transduction pathway in skeletal muscle. The insulin receptor has intrinsic 
tyrosine kinase activity and interacts with insulin receptor substrates (IRS and Shc) proteins. A number 
of "docking" proteins bind to these cellular proteins and initiate the metabolic actions of insulin [GrB-2, 
SOS, SHP-2, p110, and phosphatidylinositol-3′-kinase (PI-3-kinase)]. Insulin increases glucose transport 
through PI-3-kinase and the Cbl pathway, which promotes the translocation of intracellular vesicles 
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1.4. Type 1 DM 
 
Type 1 DM is the result of interactions of genetic, environmental, and 
immunologic factors that ultimately lead to the destruction of the pancreatic beta 
cells and insulin deficiency. Type 1 DM results from autoimmune beta cell 
destruction, and most, but not all, individuals have evidence of islet-directed 
autoimmunity. This autoimmune process is thought to be triggered by an infectious 
or environmental stimulus and to be sustained by a beta cell–specific molecule. In 
the majority, immunologic markers appear after the triggering event but before 
diabetes becomes clinically overt. Beta cell mass then begins to decrease, and 
insulin secretion progressively declines, although normal glucose tolerance is 
maintained. The rate of decline in beta cell mass varies widely among individuals, 
with some patients progressing rapidly to clinical diabetes and others evolving more 
slowly. Features of diabetes do not become evident until a majority of beta cells are 
destroyed (70–80%). At this point, residual functional beta cells exist but are 
insufficient in number to maintain glucose tolerance. The events that trigger the 
transition from glucose intolerance to frank diabetes are often associated with 
increased insulin requirements, as might occur during infections or puberty. After 
the initial clinical presentation of type 1 DM, a "honeymoon" phase may ensue 
during which time glycemic control is achieved with modest doses of insulin or, 
rarely, insulin is not needed. However, this fleeting phase of endogenous insulin 
production from residual beta cells disappears as the autoimmune process 
destroys remaining beta cells, and the individual becomes insulin deficient. Some 
individuals with long-standing type 1 diabetes produce a small amount of insulin (as 
reflected by C-peptide production) and some individuals have insulin-positive cells 
in the pancreas at autopsy. 
 
1.4.1 Genetic Considerations 
 
Susceptibility to type 1 DM involves multiple genes. The concordance of type 
1 DM in identical twins ranges between 40 and 60%, indicating that additional 
modifying factors are likely involved in determining whether diabetes develops. The 
major susceptibility gene for type 1 DM is located in the HLA region on 
chromosome 6. Polymorphisms in the HLA complex account for 40–50% of the 
genetic risk of developing type 1 DM. This region contains genes that encode the 
class II major histocompatibility complex (MHC) molecules, which present antigen 
to helper T cells and thus are involved in initiating the immune response. The ability 
of class II MHC molecules to present antigen is dependent on the amino acid 
composition of their antigen-binding sites. Amino acid substitutions may influence 
the specificity of the immune response by altering the binding affinity of different 
antigens for class II molecules. 
Most individuals with type 1 DM have the HLA DR3 and/or DR4 haplotype. 
Refinements in genotyping of HLA loci have shown that the haplotypes 
DQA1*0301, DQB1*0302, and DQB1*0201 are most strongly associated with type 1 
DM. These haplotypes are present in 40% of children with type 1 DM as compared 
to 2% of the normal U.S. population. However, most individuals with predisposing 
haplotypes do not develop diabetes. 
In addition to MHC class II associations, genome association studies have 
identified at least 20 different genetic loci that contribute susceptibility to type 1 DM 




(polymorphisms in the promoter region of the insulin gene, the CTLA-4 gene, 
interleukin-2 receptor, CTLA4, and PTPN22, etc.). Genes that confer protection 
against the development of the disease also exist. The haplotype DQA1*0102, 
DQB1*0602 is extremely rare in individuals with type 1 DM (<1%) and appears to 
provide protection from type 1 DM. 
Although the risk of developing type 1 DM is increased ten fold in relatives of 
individuals with the disease, the risk is relatively low: 3–4% if the parent has type 1 
diabetes and 5–15% in a sibling (depending on which HLA haplotypes are shared). 





Although other islet cell types [alpha cells (glucagon-producing), delta cells 
(somatostatin-producing), or PP cells (pancreatic polypeptide-producing)] are 
functionally and embryologically similar to beta cells and express most of the same 
proteins as beta cells, they are spared from the autoimmune destruction. 
Pathologically, the pancreatic islets are infiltrated with lymphocytes (a process 
termed insulitis). After all beta cells are destroyed, the inflammatory process 
abates, the islets become atrophic, and most immunologic markers disappear. 
Studies of the autoimmune process in humans and in animal models of type 1 DM 
(NOD mouse and BB rat) have identified the following abnormalities in the humoral 
and cellular arms of the immune system: (1) islet cell autoantibodies; (2) activated 
lymphocytes in the islets, peripancreatic lymph nodes, and systemic circulation; (3) 
T lymphocytes that proliferate when stimulated with islet proteins; and (4) release of 
cytokines within the insulitis. Beta cells seem to be particularly susceptible to the 
toxic effect of some cytokines [tumor necrosis factor α (TNF-α), interferon γ, and 
interleukin 1 (IL-1)]. The precise mechanisms of beta cell death are not known but 
may involve formation of nitric oxide metabolites, apoptosis, and direct CD8+ T cell 
cytotoxicity. The islet destruction is mediated by T lymphocytes rather than islet 
autoantibodies, as these antibodies do not generally react with the cell surface of 
islet cells and are not capable of transferring DM to animals. Suppression of the 
autoimmune process at the time of diagnosis of diabetes slows the decline in beta 
cell destruction, but the safety of such interventions is unknown. 
Pancreatic islet molecules targeted by the autoimmune process include 
insulin, glutamic acid decarboxylase (GAD, the biosynthetic enzyme for the 
neurotransmitter GABA), ICA-512/IA-2 (homology with tyrosine phosphatases), and 
a beta cell–specific zinc transporter (ZnT-8). Most of the auto-antigens are not beta 
cell–specific, which raises the question of how the beta cells are selectively 
destroyed. Current theories favor initiation of an autoimmune process directed at 
one beta cell molecule, which then spreads to other islet molecules as the immune 
process destroys beta cells and creates a series of secondary auto-antigens. The 
beta cells of individuals who develop type 1 DM do not differ from beta cells of 
normal individuals, since islets transplanted from a genetically identical twin are 
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1.4.3 Immunologic markers  
 
Islet cell autoantibodies (ICAs) are a composite of several different antibodies 
directed at pancreatic islet molecules such as GAD, insulin, IA-2/ICA-512, and ZnT-
8, and serve as a marker of the autoimmune process of type 1 DM. Assays for 
autoantibodies to GAD-65 are commercially available. Testing for ICAs can be 
useful in classifying the type of DM as type 1 and in identifying non-diabetic 
individuals at risk for developing type 1 DM. ICAs are present in the majority of 
individuals (>85%) diagnosed with new-onset type 1 DM, in a significant minority of 
individuals with newly diagnosed type 2 DM (5–10%), and occasionally in 
individuals with GDM (<5%). At present, the measurement of ICAs in non-diabetic 
individuals is a research tool because no treatments have been approved to 
prevent the occurrence or progression to type 1 DM. Clinical trials are testing 
interventions to slow the autoimmune beta cell destruction. 
 
1.4.4 Environmental factors  
 
Numerous environmental events have been proposed to trigger the 
autoimmune process in genetically susceptible individuals; however, none have 
been conclusively linked to diabetes. Identification of an environmental trigger has 
been difficult because the event may precede the onset of DM by several years. 
Putative environmental triggers include viruses (coxsackie, rubella, enteroviruses 
most prominently), bovine milk proteins and nitrosourea compounds. 





























1.5 Type 2 DM 
 
Insulin resistance and abnormal insulin secretion are central to the 
development of type 2 DM. Although the primary defect is controversial, most 
studies support the view that insulin resistance precedes an insulin secretory defect 
but that diabetes develops only when insulin secretion becomes inadequate. Type 
2 DM likely encompasses a range of disorders with common phenotype of 
hyperglycemia. Most of our current understanding of the pathophysiology and 
genetics is based on studies of individuals of European descent. It is becoming 
increasing apparent that DM in other ethnic groups (Asian, African, and Latin 
American) has a different, but yet undefined, pathophysiology. In these groups, DM 
that is ketosisprone (often obese) or ketosis-resistant (often lean) is commonly 
seen. 
 
1.5.1 Genetic Considerations 
 
Type 2 DM has a strong genetic component. The concordance of type 2 DM 
in identical twins is between 70 and 90%. Individuals with a parent with type 2 DM 
have an increased risk of diabetes; if both parents have type 2 DM, the risk 
approaches 40%. Insulin resistance, as demonstrated by reduced glucose 
utilization in skeletal muscle, is present in many non-diabetic, first-degree relatives 
of individuals with type 2 DM. The disease is polygenic and multifactorial, since in 
addition to genetic susceptibility, environmental factors (such as obesity, nutrition, 
and physical activity) modulate the phenotype. The genes that predispose to type 2 
DM are incompletely identified, but recent genome-wide association studies have 
identified a large number of genes that convey a relatively small risk for type 2 DM 
(>20 genes, each with a relative risk of 1.06–1.5). Most prominent is a variant of the 
transcription factor 7–like 2 gene that has been associated with type 2 diabetes in 
several populations and with impaired glucose tolerance in one population at high 
risk for diabetes. Genetic polymorphisms associated with type 2 diabetes have also 
been found in the genes encoding the peroxisome proliferators–activated receptor-
γ, inward rectifying potassium channel, zinc transporter, IRS, and calpain 10. The 
mechanisms by which these genetic loci increase the susceptibility to type 2 
diabetes are not clear, but most are predicted to alter islet function or development 
or insulin secretion. While the genetic susceptibility to type 2 diabetes is under 
active investigation (estimation that <10% of genetic risk is determined by loci 
identified thus far), it is currently not possible to use a combination of known 
genetic loci to predict type 2 diabetes. 
 
1.5.2 Pathophysiology  
 
Type 2 DM is characterized by impaired insulin secretion, insulin resistance, 
excessive hepatic glucose production, and abnormal fat metabolism. Obesity, 
particularly visceral or central (as evidenced by the hip-waist ratio), is very common 
in type 2 DM (80% or more are obese). In the early stages of the disorder, glucose 
tolerance remains near-normal, despite insulin resistance, because the pancreatic 
beta cells compensate by increasing insulin output. As insulin resistance and 
compensatory hyperinsulinemia progress, the pancreatic islets in certain individuals 
are unable to sustain the hyperinsulinemic state. A further decline in insulin 
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secretion and an increase in hepatic glucose production lead to overt diabetes with 
fasting hyperglycemia. Ultimately, beta cell failure ensues. 
 
1.5.3 Abnormal Muscle and Fat Metabolism 
 
Insulin resistance, the decreased ability of insulin to act effectively on target 
tissues (especially muscle, liver, and fat), is a prominent feature of type 2 DM and 
results from a combination of genetic susceptibility and obesity. Insulin resistance 
impairs glucose utilization by insulin-sensitive tissues and increases hepatic 
glucose output; both effects contribute to the hyperglycemia. Increased hepatic 
glucose output predominantly accounts for increased FPG levels, whereas 
decreased peripheral glucose usage results in postprandial hyperglycemia. In 
skeletal muscle, there is a greater impairment in non-oxidative glucose usage 
(glycogen formation) than in oxidative glucose metabolism through glycolysis. 
Glucose metabolism in insulin-independent tissues is not altered in type 2 DM. 
The precise molecular mechanism leading to insulin resistance in type 2 DM 
has not been elucidated. Insulin receptor levels and tyrosine kinase activity in 
skeletal muscle are reduced, but these alterations are most likely secondary to 
hyperinsulinemia and are not a primary defect. Therefore, "post-receptor" defects in 
insulin-regulated phosphorylation/dephosphorylation appear to play the 
predominant role in insulin resistance. For example, a PI-3-kinase signaling defect 
might reduce translocation of GLUT4 to the plasma membrane. Other abnormalities 
include the accumulation of lipid within skeletal myocytes, which may impair 
mitochondrial oxidative phosphorylation and reduce insulin-stimulated 
mitochondrial ATP production. Impaired fatty acid oxidation and lipid accumulation 
within skeletal myocytes also may generate reactive oxygen species such as lipid 
peroxides. Of note, not all insulin signal transduction pathways are resistant to the 
effects of insulin (e.g., those controlling cell growth and differentiation using the 
mitogenic-activated protein kinase pathway). Consequently, hyperinsulinemia may 
increase the insulin action through these pathways, potentially accelerating 
diabetes-related conditions such as atherosclerosis. 
The obesity accompanying type 2 DM, particularly in a central or visceral 
location, is thought to be part of the pathogenic process. The increased adipocyte 
mass leads to increased levels of circulating free fatty acids and other fat cell 
products. For example, adipocytes secrete a number of biologic products (non-
esterified free fatty acids, retinol-binding protein 4, leptin, TNF-α, resistin, and 
adiponectin). In addition to regulating body weight, appetite, and energy 
expenditure, adipokines also modulate insulin sensitivity. The increased production 
of free fatty acids and some adipokines may cause insulin resistance in skeletal 
muscle and liver. For example, free fatty acids impair glucose utilization in skeletal 
muscle, promote glucose production by the liver, and impair beta cell function. In 
contrast, the production by adipocytes of adiponectin, an insulin-sensitizing peptide, 
is reduced in obesity, and this may contribute to hepatic insulin resistance. 
Adipocyte products and adipokines also produce an inflammatory state and may 
explain why markers of inflammation such as IL-6 and C-reactive protein are often 
elevated in type 2 DM. In addition, inflammatory cells have been found infiltrating 
adipose tissue. Inhibition of inflammatory signaling pathways such as the nuclear 
factor κB (NF-κB) pathway appears to reduce insulin resistance and improve 
hyper-glycemia in animal models. 




1.5.4 Impaired Insulin Secretion 
 
Insulin secretion and sensitivity are interrelated. In type 2 DM, insulin 
secretion initially increases in response to insulin resistance to maintain normal 
glucose tolerance. Initially, the insulin secretory defect is mild and selectively 
involves glucose-stimulated insulin secretion. The response to other non-glucose 
secretagogues, such as arginine, is preserved. Abnormalities in proinsulin 
processing is reflected by increased secretion of proinsulin in type 2 diabetes. 
Eventually, the insulin secretory defect progresses to a state of inadequate insulin 
secretion. The reason(s) for the decline in insulin secretory capacity in type 2 DM is 
unclear. The assumption is that a second genetic defect—superimposed upon 
insulin resistance—leads to beta cell failure. Beta cell mass is decreased by 
approximately 50% in individuals with long-standing type 2 diabetes. Islet amyloid 
polypeptide or amylin is co-secreted by the beta cell and forms the amyloid fibrillar 
deposit found in the islets of individuals with long-standing type 2 DM. Whether 
such islet amyloid deposits are a primary or secondary event is not known. The 
metabolic environment of diabetes may also negatively impact islet function. For 
example, chronic hyperglycemia paradoxically impairs islet function ("glucose 
toxicity") and leads to a worsening of hyperglycemia. Improvement in glycemic 
control is often associated with improved islet function. In addition, elevation of free 
fatty acid levels ("lipotoxicity") and dietary fat may also worsen islet function. 
 
1.5.5 Increased Hepatic Glucose and Lipid Production 
 
In type 2 DM, insulin resistance in the liver reflects the failure of 
hyperinsulinemia to suppress gluconeogenesis, which results in fasting 
hyperglycemia and decreased glycogen storage by the liver in the postprandial 
state. Increased hepatic glucose production occurs early in the course of diabetes, 
though likely after the onset of insulin secretory abnormalities and insulin resistance 
in skeletal muscle. As a result of insulin resistance in adipose tissue, lipolysis and 
free fatty acid flux from adipocytes are increased, leading to increased lipid [very 
low density lipoprotein (VLDL) and triglyceride] synthesis in hepatocytes. This lipid 
storage or steatosis in the liver may lead to non-alcoholic fatty liver disease and 
abnormal liver function tests. This is also responsible for the dyslipidemia found in 
type 2 DM [elevated triglycerides, reduced high-density lipoprotein (HDL), and 
increased small dense low-density lipoprotein (LDL) particles] (Harrison's Principles 
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1.6 INSULIN RESISTANCE SYNDROMES 
 
The insulin resistance condition comprises a spectrum of disorders, with 
hyperglycemia representing one of the most readily diagnosed features. The 
metabolic syndrome, the insulin resistance syndrome, or syndrome X are terms 
used to describe a constellation of metabolic derangements that includes insulin 
resistance, hypertension, dyslipidemia (decreased HDL and elevated triglycerides), 
central or visceral obesity, type 2 diabetes or IGT/IFG, and accelerated 
cardiovascular disease. 
A number of relatively rare forms of severe insulin resistance include features 
of type 2 DM or IGT. Mutations in the insulin receptor that interfere with binding or 
signal transduction are a rare cause of insulin resistance. Acanthosis nigricans and 
signs of hyperandrogenism (hirsutism, acne, and oligomenorrhea in women) are 
also common physical features. Two distinct syndromes of severe insulin 
resistance have been described in adults: (1) type A, which affects young women 
and is characterized by severe hyperinsulinemia, obesity, and features of 
hyperandrogenism; and (2) type B, which affects middle-aged women and is 
characterized by severe hyperinsulinemia, features of hyperandrogenism, and 
autoimmune disorders. Individuals with the type A insulin resistance syndrome 
have an undefined defect in the insulin-signaling pathway; individuals with the type 
B insulin resistance syndrome have autoantibodies directed at the insulin receptor. 
These receptor autoantibodies may block insulin binding or may stimulate the 
insulin receptor, leading to intermittent hypoglycemia (Harrison's Principles of 
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2.1 Biochemistry and molecular cell biology 
 
All forms of diabetes, both inherited and acquired, are characterized by 
hyperglycemia, a relative or absolute lack of insulin, and the development of 
diabetes-specific microvascular pathology in the retina, renal glomerulus, and 
peripheral nerve. Diabetes is also associated with accelerated atherosclerotic 
macrovascular disease affecting arteries that supply the heart, brain, and lower 
extremities. The risk of cardiovascular complications is increased by two-fold to six-
fold in subjects with diabetes. Overall, life expectancy is about 7 to 10 years shorter 
than for people without diabetes mellitus because of increased mortality from 
diabetic complications (Skyler, 1996).  
 
2.1.2 Shared Pathophysiologic Features of Microvascular 
Complications 
 
In the retina, glomerulus, and vasa nervorum, diabetes-specific microvascular 
disease is characterized by similar pathophysiologic features. Although all diabetic 
cells are exposed to elevated levels of plasma glucose, hyperglycemic damage is 
limited to those cell types (e.g., endothelial cells) that develop intracellular 
hyperglycemia. Endothelial cells develop intracellular hyperglycemia because, 
unlike many other cells, they cannot downregulate glucose transport when exposed 
to extracellular hyperglycemia. As illustrated in Figure 2.1, vascular smooth muscle 
cells (VSMC), which are not damaged by hyperglycemia, show an inverse 
relationship between extracellular glucose concentration and subsequent rate of 
glucose transport measured as 2-deoxyglucose uptake (Fig. 2.1, upper part). In 
contrast, vascular endothelial cells show no significant change in subsequent rate 
of glucose transport after exposure to elevated glucose concentrations (see Fig. 
2.1, lower part)(Kaiser et al., 1993).  
 





Figure 2.1 Lack of downregulation of glucose transport in cells affected by diabetic complications. Upper 
panel, 2-deoxyglucose (2DG) uptake in vascular smooth muscle cells pre-exposed to 1.2, 5.5, or 22 
mmol/l glucose. Lower panel, 2DG uptake in bovine endothelial cells pre-exposed to 1.2, 5.5, or 22 
mmol/l glucose. (Kaiser et al., 1993) 
 
2.1.3 Abnormal Endothelial Cell Function 
 
Early in the course of diabetes mellitus, before structural changes are 
evident, hyperglycemia causes abnormalities in blood flow and vascular 
permeability in the retina, glomerulus, and peripheral nerve vasa nervorum (Tooke 
et al., 1996; Kihara et al., 1991). The increase in blood flow and intracapillary 
pressure is thought to reflect a hyperglycemia-induced decrease in nitric oxide (NO) 
production on the efferent side of capillary beds and possibly an increased 
sensitivity to angiotensin II. Morover, the common pathophysiologic feature of 
diabetic microvascular disease is progressive narrowing and eventual occlusion of 
vascular lumina, which results in inadequate perfusion and function of the affected 
tissues.  
Early hyperglycemia-induced microvascular hypertension and increased 
vascular permeability contribute to irreversible microvessel occlusion by three 
processes 
• The first process is an abnormal leakage of periodic acid–Schiff 
(PAS)-positive, carbohydrate-containing plasma proteins, which are 
deposited in the capillary wall and can stimulate perivascular cells such as 
pericytes and mesangial cells to elaborate growth factors and extracellular 
matrix. 
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• The second process is extravasation of growth factors, such as 
transforming growth factor-β1 (TGF-β1), which directly stimulates 
overproduction of extracellular matrix components (Kopp et al., 1996) and 
can induce apoptosis in certain complication-relevant cell types. 
 
 
• The third process is hypertension-induced stimulation of pathologic 
gene expression by endothelial cells and supporting cells, which include 
GLUT1, growth factors, growth factor receptors, extracellular matrix 
components, and adhesion molecules that can activate circulating 




2.1.4 Microvascular Cell Loss and Vessel Occlusion 
 
The progressive narrowing and occlusion of diabetic microvascular lumina 
are also accompanied by microvascular cell loss. In the retina, diabetes mellitus 
induces programmed cell death of Müller cells and ganglion cells (Hammes et al., 
1995), pericytes, and endothelial cells (Mizutani et al., 1996). In the glomerulus, 
declining renal function is associated with widespread capillary occlusion and 
podocyte loss, but the mechanisms underlying glomerular cell loss are not yet 
known. In the vasa nervorum, degeneration of endothelial cells and pericytes occur 
(Giannini and Dyck, 1993), and these microvascular changes appear to precede 
the development of diabetic peripheral neuropathy (Giannini and Dyck, 1995).  
 
2.1.5 Genetic Determinants of Susceptibility to Microvascular 
Complications 
 
Clinicians have long observed that different patients with similar duration and 
degree of hyperglycemia differ markedly in their susceptibility to microvascular 
complications. Such observations suggested that genetic differences exist that 
affected the pathways by which hyperglycemia damages microvascular cells.  
A role for a genetic determinant of susceptibility to diabetic nephropathy is 
most strongly supported by familial clustering, with an estimated heritability of at 
least 40% (Wagenknecht et al., 2001a). In two studies of families in which two or 
more siblings had T1DM, the risk of nephropathy in a diabetic sibling was 83% or 
72% if the probrand diabetic sibling had advanced diabetic nephropathy, but only 
17% or 22% if the index patient did not have diabetic nephropathy (Fig. 2.2) 
(Seaquist et al., 1989; Quinn et al., 1996) or retinopathy.  
 




Figure 2.2 Familial clustering of diabetic nephropathy. Prevalence of diabetic nephropathy in two 
studies of diabetic siblings of probands with or without diabetic nephropathy. Adapted from (Seaquist et 
al., 1989; Quinn et al., 1996) 
 
Numerous associations have been made between various genetic 
polymorphisms and the risk of diabetic complications. Examples include the 5′ 
insulin gene polymorphism (Raffel et al., 1991), the G2m23+ immunoglobulin 
allotype (Stewart et al., 1993), angiotensin-converting enzyme (ACE) 
insertion/deletion polymorphisms (Marre et al., 1994; Marre et al., 1997), HLA-
DQB10201/0302 alleles (Agardh et al., 1996), polymorphisms of the aldose 
reductase gene (Oates and Mylari, 1999), and a polymorphic CCTTT(n) repeat of 
nitric oxide synthase 2A (NOS2A) (Warpeha et al., 1999). An individual-based 
genetic association study of subjects from the DCCT/EDIC found that multiple 
variations in superoxide dismutase 1 were significantly associated with persistent 
microalbuminuria and severe nephropathy (Al Kateb et al., 2008). In all of these 
studies, there was no indication that the polymorphic gene actually plays a 
functional role rather than simply being in linkage disequilibrium with the locus 
encoding the unidentified relevant genes. 
As genes are identified that affect susceptibility to diabetic complications, a 
new area of research has emerged that will make it possible to identify genetic 
modifiers of the clinical manifestations of complications. 
 
2.2 Pathophysiologic Features of Macrovascular Complications 
 
Unlike microvascular disease, which occurs only in patients with diabetes 
mellitus, macrovascular disease resembles that in subjects without diabetes. 
However, subjects with diabetes have more rapidly progressive and extensive CVD 
than non-diabetic persons (Granger et al., 1993).  
The importance of hyperglycemia in the pathogenesis of diabetic 
macrovascular disease is suggested by studies that show how hyperglycemia is a 
continuous risk factor for macrovascular disease (Gerstein, 1999; Gall et al., 1995; 
Kuusisto et al., 1994; Salomaa et al., 1995; Laakso and Kuusisto, 1996). 
However, data from the United Kingdom Prospective Diabetes Study 
(UKPDS) show for microvascular disease end points, that there is an almost 10-fold 
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increase in risk as HbA1c increases from 5.5% to 9.5%, whereas over the same 
HbA1c range, macrovascular risk increases only about two-fold (1998). 
Hyperglycemia is not nearly as central a determinant of diabetic macrovascular 
disease as it is in microvascular disease like insulin resistance. Insulin resistance is 
commonly associated with a pro-atherogenic dyslipidemia with a characteristic 
lipoprotein profile that includes a high level of very-low-density lipoprotein (VLDL) 
and low levels of high-density lipoprotein (HDL) and small, dense low-density 
lipoprotein (LDL). Both low HDL and small, dense LDL are independent risk factors 
for macrovascular disease. This profile arises as a direct result of increased net 




Figure 2.3 Schematic summary relating insulin resistance (IR) to the characteristic dyslipidemia of type 
2 diabetes mellitus. IR at the adipocyte results in increased free fatty acid (FFA) release. Increased FFA 
flux stimulates secretion of very-low-density lipoprotein (VLDL), causing hypertriglyceridemia (TG). 
VLDL stimulates a reciprocal exchange of TG to cholesteryl ester (CE) from both high-density lipoprotein 
(HDL) and low-density lipoprotein (LDL), catalyzed by CE transfer protein (CETP). TG-enriched HDL 
dissociates from apolipoprotein (Apo) A-1, leaving less HDL for reverse cholesterol transport TG-
enriched. LDL serves as a substrate for lipases that convert it to atherogenic small, dense LDL particles 
(SD LDL). (Ginsberg, 2000) 
 
2.2.1 Impaired Collateral Blood Vessel Formation from Bone 
Marrow Progenitor Cells 
 
It has become apparent that diabetic complications result not only from 
damage to vascular cells but also from a defective repair process. Normally, in 
response to acute ischemia, new blood vessel growth rescues stunned areas of the 
heart or central nervous system, reducing morbidity and mortality. In response to 
chronic ischemia, collateral vessel development reduces the size and severity of 
subsequent infarction. In response to ischemia, circulating endothelial progenitor 
cells from the bone marrow promote the regeneration of blood vessels, acting in 
concert with cells and extracellular matrix at the site of injury. In experimental 
diabetes, however, these circulating endothelial progenitor cells are depleted and 
dysfunctional. As a result, diabetic animals have decreased vascular density after 
hind limb ischemia. Similarly, in human diabetes, endothelial progenitor cells are 
also depleted and dysfunctional (Nathan et al., 2005). 
Diabetes is associated with poor outcomes after acute vascular occlusive 
events. This results in part from a failure to form adequate compensatory 
microvasculature in response to ischemia.  
High glucose induces decreased HIF-1α functional activity by impaired 
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formation of the HIF-1α heterodimer with arylhydrocarbon receptor nuclear 
translocator (ARNT) and by impaired binding of the coactivator p300 to the HIF-1α–
ARNT heterodimer. Hyperglycemia-induced covalent modification of p300 by the 
dicarbonyl metabolite methylglyoxal is responsible for this decreased association. 
In diabetic mouse models of impaired angiogenesis and wound healing, decreasing 
mitrochondrial formation of reactive oxygen species (ROS) normalizes both 
ischemia-induced new vessel formation and wound healing (Krolewski et al., 1996; 
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2.3 Mechanisms of Hyperglycemia-Induced Damage 
 
2.3.1 Increased Polyol Pathway Flux 
 
Aldose reductase is a NADPH-dependent oxidoreductase that catalyzed the 
reducion of a wide variety of carbonyl compounds, including glucose. Aldose 
reductase has a low-affinity (high Michaelis constant [Km]) for glucose and at the 
normal glucose concentrations, found in nondiabetic patients, the metabolism of 
glucose by this pathway constitutes a small percentage of total glucose utilization. 
In a hyperglycemic environment, however, increased intracellular glucose results in 
increased enzymatic conversion to the polyalcohol sorbitol, with concomitant 
decreases in NADPH. In the polyol pathway, sorbitol is oxidized to fructose by the 
enzyme sorbitol dehydrogenase, with nicotinamide adenine dinucleotide (NAD+) 
reduced to NADH. A number of mechanisms have been proposed to explain the 
potential detrimental effects of hyperglycemia-induced increases in polyol pathway 
flux. These include sorbitol-induced osmotic stress, decreased activity of the 
sodium-potassium adenosine triphosphatase (Na+,K+-ATPase) pump, increased 
cytosolic NADH/NAD+, and decreased cytosolic NADPH. More recently, it has been 
proposed that oxidation of sorbitol by NAD+ increases the cytosolic NADH/ NAD+ 
ratio, thereby inhibiting activity of the enzyme glyceraldehyde-3-phosphate 
dehydrogenase (GADPH) and increasing the concentrations of triose phosphate 
(Williamson et al., 1993). Elevated triose phosphate concentrations could increase 
the formation of both methylglyoxal, a precursor of AGEs, and (via α-glycerol-3-
phosphate) diacylglycerol (DAG) thus activating PKC. It has also been proposed 
that reduction of glucose to sorbitol by NADPH consumes the cofactor NADPH. 
Because NADPH is required for regeneration of reduced glutathione, this could 
induce or exacerbate intracellular oxidative stress. Indeed, overexpression of 
human aldose reductase increased atherosclerosis in diabetic mice and reduces 
the expression of genes that regulate regeneration of glutathione (Vikramadithyan 
et al., 2005). In vivo studies of polyol pathway inhibition have yielded inconsistent 
results. In a 5-year study in dogs, aldose reductase inhibition prevented diabetic 
neuropathy but failed to prevent retinopathy or capillary basement membrane 
thickening in the retina, kidney, or muscle (Engerman et al., 1994). Several 
negative clinical trials have questioned the relevance of this mechanism in humans 
(Trial of sorbinil 1990). However, the positive effect of aldose reductase inhibition 
on diabetic neuropathy has been confirmed in humans in a rigorous multidose, 
placebo-controlled trial with the potent aldose reductase inhibitor, zenarestat 
(Greene et al., 1999).  
 
2.3.2 Increased Intracellular Formation of Advanced Glycation 
End Products 
 
AGEs were originally thought to arise from non-enzymatic reactions between 
extracellular proteins and glucose. However, the rate of AGE formation from 
glucose is orders of magnitude slower than the rate of AGE formation from glucose-
derived dicarbonyl precursors generated intracellularly, and it now seems likely that 
intracellular hyperglycemia is the primary initiating event in the formation of both 
intracellular and extracellular AGEs (Degenhardt et al., 1998). AGEs can arise from 
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intracellular auto-oxidation of glucose to glyoxal (Wells-Knecht et al., 1995), 
decomposition of the Amadori product to 3-deoxyglucosone, and fragmentation of 
glyceraldehyde-3-phosphate to methylglyoxal (Fig. 2.4) (Takahashi et al., 1993). 
Intracellular production of AGE precursors damages target cells by three general 
mechanisms:  
• Intracellular proteins modified by AGEs have altered function. 
• Extracellular matrix components modified by AGE precursors interact 
abnormally with other matrix components and with matrix receptors 
(integrins) on cells.  
• Plasma proteins modified by AGE precursors bind to AGE receptors on 
cells such as macrophages, inducing receptor-mediated ROS production.  
This AGE-receptor ligation activates the pleiotropic transcription factor nuclear 




Figure 2.4 Potential pathways leading to the formation of advanced glycation end products (AGEs) from 
intracellular dicarbonyl precursors. Glyoxal arises from the auto-oxidation of glucose, 3-deoxyglucosone 
arises from decomposition of the Amadori product, and methylglyoxal arises from fragmentation of 
glyceraldehyde-3-phosphate. These reactive dicarbonyls react with amino groups of proteins to form 
AGEs. Methylglyoxal and glyoxal are detoxified by the glyoxalase system. (Adapted from Shinohara 
M,Thornalley PJ, Giardino I, et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits 
intracellular advanced glycation end-product formation and prevents hyperglycemia-induced increases 
in macromolecular endocytosis. J Clin Invest. 1998;101:1142-1147.) 
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2.3.3 Hyperglycemia-Induced Protein Kinase C Activation.  
 
The PKC family comprises at least 11 isoforms, 9 of which are activated by 
the lipid second messenger, DAG. Intracellular hyperglycemia increases DAG 
content in cultured microvascular cells and in the retina and renal glomeruli of 
diabetic animals (Inoguchi et al., 1992; Craven et al., 1990; Shiba et al., 1993).  
In early experimental diabetes, activation of PKC-β isoforms has been shown 
to mediate retinal and renal blood flow abnormalities (Ishii et al., 1996), perhaps by 
depressing NO production and increasing endothelin-1 activity. 
In addition to affecting hyperglycemia-induced abnormalities of blood flow 
and permeability, activation of PKC contributes to increased microvascular matrix 
protein accumulation by inducing the expression of TGF-β1, fibronectin, and α1 
type IV collagen in cultured mesangial cells (Pugliese et al., 1994; Studer et al., 
1993) and in glomeruli of diabetic rats (Craven et al., 1994).  
 
2.3.4 Increased Hexosamine Pathway Flux 
 
A fourth hypothesis about how hyperglycemia causes diabetic complications 
(Sayeski and Kudlow, 1996a; Kolm-Litty et al., 1998; Daniels et al., 1993; McClain 
et al., 1992) states that glucose is shunted into the hexosamine pathway. In this 
pathway, fructose-6-phosphate is diverted from glycolysis to provide substrate for 
the rate-limiting enzyme of this pathway, glutamine:fructose 6-phosphate 
amidotransferase (GFAT). GFAT converts fructose 6-phosphate to glucosamine 6-
phosphate, which is then converted to UDP-N-Acetylglucosamine. Specific O-
GlcNAc transferases use this for post-translational modification of specific serine 
and threonine residues on cytoplasmic and nuclear proteins by O-GlcNAc. 
Inhibition of GFAT blocks hyperglycemia-induced increases in the transcription of 
both TGF-α and TGF-β1 (Sayeski and Kudlow, 1996b). 
Although it is not entirely clear how increased flux through the hexosamine 
pathway mediates hyperglycemia-induced increases in the gene transcription of 
key genes such as TGF-α, TGF-β1, and PAI-1, it has been shown that 
hyperglycemia causes a 4-fold increase in O-GlcNAcylation of the transcription 
factor Sp1, which mediates hyperglycemia-induced activation of the PAI-1 promoter 
in vascular smooth muscle cells (Chen et al., 1998) and of TGF-β1 and PAI-1 in 
arterial endothelial cells (Du et al., 2000a). 
Of particular relevance to diabetic vascular complications is the inhibition of 
eNOS activity in arterial endothelial cells by O-GlcNAcylation at the Akt activation 
site of eNOS protein (Yamagishi et al., 2001; Hart, 1997; Musicki et al., 2005). 
Hyperglycemia also increases GFAT activity in aortic smooth muscle cells, which 
increases O-GlcNAc-modification of several proteins in these cells (Akimoto et al., 
2001). 
Finally, diabetic hyperglycemia impairs cardiomyocyte calcium cycling 
through increased nuclear O-GlcNAcylation, which reduced sarcoplasmic reticulum 
Ca(2+)-ATPase 2a (SERCA2a) mRNA and protein expression, and decreased 
SERCA2a promoter activity (Clark et al., 2003). In isolated perfused rat hearts, 
increased GlcNAcylation inhibited phenylephrine-induced inotropy by impairing 
capacitative Ca2+ entry (CCE), the influx of Ca2+ through plasma membrane 
channels activated in response to depletion of endoplasmic or sarcoplasmic 
reticulum Ca2+ stores (Pang et al., 2004). 




2.4 Different Hyperglycemia-Induced Pathogenic Mechanisms 
Reflect a Single Process 
 
Although specific inhibitors of aldose reductase activity, AGE formation, and 
PKC activation ameliorate various diabetes-induced abnormalities in animal 
models, there has been no apparent common element linking the four mechanisms 
of hyperglycemia-induced damage.  
Hyperglycemia increases ROS production inside cultured bovine aortic 
endothelial cells. To understand how this occurs, a brief overview of glucose 
metabolism is helpful (Fig. 2.5).  
 
 
Figure 2.5 Production of superoxide by the mitochondrial electron transport chain. Increased 
hyperglycemia-derived electron donors from the tricarboxylic acid cycle (NADH and FADH2) generate a 
high mitochondrial membrane potential (Δµ H+) by pumping protons across the mitochondrial inner 
membrane. This inhibits electron transport at complex III and increases the half-life of free radical 
intermediates of coenzyme Q, which reduce O2 to superoxide. ADP, adenosine diphosphate;ATP, 
adenosine triphosphate; Mn-SOD, manganese superoxide dismutase; NAD+, nicotinamide adenine 
dinucleotide; NADH, reduced nicotinamide adenine dinucleotide; Pi, inorganic phosphate; UCP, 
uncoupling protein. (From Boss O, Hagen T, Lowell BB. Uncoupling proteins 2 and 3: potential 
regulators of mitochondrial energy metabolism. Diabetes. 2000;49:143-156.) 
 
Intracellular glucose oxidation begins with glycolysis in the cytoplasm, which 
generates NADH and pyruvate. Cytoplasmic NADH can donate reducing 
equivalents to the mitochondrial electron transport chain via two shuttle systems, or 
it can reduce pyruvate to lactate, which exits the cell to provide substrate for 
hepatic gluconeogen- esis. Pyruvate can also be transported into the mitochondria, 
where it is oxidized by the tricarboxylic acid (TCA) cycle to produce CO2, H2O, four 
molecules of NADH, and one molecule of reduced flavin adenine dinucleotide 
(FADH2). Mitochondrial NADH and FADH2 provide energy for ATP production via 
oxidative phosphorylation by the electron transport chain. 
Electron flow through the mitochondrial electron transport chain is carried out 
by four inner membrane–associated enzyme complexes, plus cytochrome c and 
the mobile carrier, ubiquinone (Wallace, 1992). NADH derived from cytosolic 
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glucose oxidation and mitochondrial TCA cycle activity donates electrons to 
NADH:ubiquinone oxidoreductase (complex I). Complex I ultimately transfers its 
electrons to ubiquinone. Ubiquinone can also be reduced by electrons donated 
from several FADH2-containing dehydrogenases, including succinate:ubiquinone 
oxidoreductase (complex II) and glycerol-3-phosphate dehydrogenase. Electrons 
from reduced ubiquinone are then transferred to ubiquinol:cytochrome-c 
oxidoreductase (complex III) by the ubisemiquinone radical-generating Q cycle 
(Trumpower, 1990). Electron transport then proceeds through cytochrome c, 
cytochrome-c oxidase (complex IV), and, finally, molecular oxygen. 
Electron transfer through complexes I, III, and IV generates a proton gradient 
that drives ATP synthase (complex V). When the electrochemical potential 
difference generated by this proton gradient is high, the life of superoxide-
generating electron transport intermediates such as ubisemiquinone is prolonged. 
There appears to be a threshold value above which superoxide production is 
markedly increased (Fig. 2.5) (Korshunov et al., 1997). 
Investigators using inhibitors of both the shuttle that transfers cytosolic NADH 
into mitochondria and the transporter that transfers cytosolic pyruvate into the 
mitochondria showed that the TCA cycle is the source of hyperglycemia-induced 
ROS in endothelial cells. Overexpression of uncoupling protein 1 (UCP-1), a 
specific protein uncoupler of oxidative phosphorylation capable of collapsing the 
proton electrochemical gradient (Casteilla et al., 1990), also prevented the effect of 
hyperglycemia. These results demonstrated that hyperglycemia-induced 
intracellular ROS are produced by the proton electrochemical gradient generated 
by the mitochondrial electron transport chain. Overexpression of manganese 
superoxide dismutase (Mn-SOD), the mitochondrial form of this antioxidant enzyme 
(Manna et al., 1998), prevents the effect of hyperglycemia. Prevention of 
mitochondrial superoxide production also completely prevents activation of the 
polyol pathway, AGE formation, PKC, and the hexosamine pathway. 
 
Therefore, hyperglycemia-induced mitochondrial production of ROS is both 
necessary and sufficient for activation of each of these pathways. 
How does hyperglycemia-induced ROS activate AGE formation, PKC, the 
hexosamine pathway, and the polyol pathway?  
Diabetes in animals and patients, and hyperglycemia in cells, all decrease 
the activity of the key glycolytic enzyme GAPDH in cell types that develop 
intracellular hyperglycemia. Inhibition of GAPDH activity by hyperglycemia does not 
occur when mitochondrial overproduction of superoxide is prevented by either 
UCP-1 or MnSOD (Nascimento et al., 2006). When GAPDH activity is inhibited, the 
levels of all the glycolytic intermediates that are upstream of GAPDH increase. This 
then increases the flux into the 5 pathways described earlier. Increased levels of 
the upstream glycolytic metabolite glyceraldehyde 3-phosphate activates 2 major 
pathways. It activates the AGE pathway because the major intracellular AGE 
precursor methylglyoxal is formed non-enzymatically from glyceraldehyde 3-
phosphate. Hyperglycemia-induced methylglyoxal formation has recently been 
shown to cause both increased expression of the RAGE and its activating ligands 
S100 calgranulins and HMGB1 (Yao and Brownlee, 2010). 
Increased glyceraldehyde 3-phosphate also activates the classic PKC 
pathway, because the physiological activator of PKC, DAG, is also formed from 
glyceraldehyde 3-phosphate. Further upstream, levels of the glycolytic metabolite 
fructose 6-phosphate increase, which then increases flux through the hexosamine 
pathway, where fructose 6-phosphate is converted by the enzyme GFAT to UDP–
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N-acetylglucosamine (UDP-GlcNAc). Finally, inhibition of GAPDH increases 
intracellular levels of the first glycolytic metabolite, glucose. This increases flux 
through the polyol pathway, where the enzyme aldose reductase reduces it (or 
glyceraldehyde 3-phosphate), consuming NADPH in the process. Inhibition of 
GAPDH activity in 5 mmol/L glucose using antisense DNA elevates the activity of 
each of the major pathways of hyperglycemic damage to the same extent as that 
induced by hyperglycemia (Fig. 2.6). 
 
 
Figure 2.6 Schematic showing elements of the unifying mechanism of hyperglycemia-induced cellular 
damage. (Adpted from Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. 
Diabetes. 2005; 54: 1615–1625). 
 
Hyperglycemia-induced superoxide inhibits GAPDH activity in vivo by 
modifying the enzyme with polymers of ADP-ribose (Du et al., 2003). By inhibiting 
mitochondrial superoxide production with either UCP-1 or MnSOD, both 
modification of GAPDH by poly(ADP-ribose) and reduction of its activity by 
hyperglycemia were prevented. Most importantly, both modification of GAPDH by 
poly(ADP-ribose) and reduction of its activity by hyperglycemia were also 
prevented by a specific inhibitor of poly(ADP-ribose) polymerase (PARP), the 
enzyme that makes these polymers of ADP-ribose. Normally, PARP resides in the 
nucleus in an inactive form, waiting for DNA damage to activate it. When increased 
intracellular glucose generates increased ROS in the mitochondria, free radicals 
induce DNA strand breaks, thereby activating PARP. Both hyperglycemia-induced 
processes are prevented by either UCP-1 or MnSOD (Du et al., 2000b).Once 
activated, PARP splits the NAD+ molecule into its 2 component parts: nicotinic acid 
and ADP-ribose. PARP then proceeds to make polymers of ADP-ribose, which 
accumulate on GAPDH and other nuclear proteins. GAPDH is commonly thought to 
reside exclusively in the cytosol. However, it normally shuttles in and out of the 
nucleus, where it plays a critical role in DNA repair (Fig. 2.6) (Du et al., 2003). 
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The first investigation of a metabolic memory was reported over 20 years ago 
(Engerman and Kern, 1987) in the retina of diabetic dogs who were switched to 
good glucose control after either 2 months or 2.5 years of poor glucose control and 
then analyzed at 5 years after beginning the study. The animals switched to good 
glucose control at 2 months had little evidence of retinopathy and identical HbA1c, 
as their control counterparts receiving good glucose control throughout the study. In 
contrast, the animals switched to good control at 2.5 years had a similar incidence 
of retinopathy as their control counterparts who received poor glucose control 
throughout the 5-years study. Just after this first study was published, a study (Roy 
et al., 1990) showed that there was a memory of basement membrane collagen IV, 
fibronectin mRNA induction in isolated endothelial cells and in the kidneys of 
streptozotocin (STZ)-induced diabetic rats 1 week after glucose normalization after 
2 weeks of high glucose.  
This metabolic memory phenomenon emerged, clinically, when the results of 
a large type 1 diabetes clinical trial, the Diabetes Complications and Control Trial 
(DCCT) and its follow-up Epidemiology of Diabetes Interventions and 
Complications (EDIC) trial, came to light. In the DCCT, type 1 diabetic patients 
were placed on either standard or intensive treatment regimens to normalize their 
glucose levels. Because the progression of microvascular complications was so 
profoundly reduced in patients with intensive glucose control, the DCCT ended 
early after a mean time of 6.5 years and all patients were placed onto intensive 
therapy (DCCT study 1993). Then in the EDIC follow-up trial with the same patient 
population, it was found that patients on the standard treatment regimen during the 
DCCT still had a higher incidence of microvascular diabetic complications such as 
nephropathy and retinopathy compared with their counterparts receiving intensive 
therapy throughout the trial several years after switching to intensive therapy, 
despite the fact that the mean HbA1c levels of the groups were nearly equivalent 
(EDIC study 2002; 2003). HbA1c and duration of diabetes (glycemic exposure) 
explained only about 11% of the variation in retinopathy risk for the entire study 
population, suggesting that the remaining 89% of the variation in risk is presumably 
explained by other factors independent of HbA1C (Lachin et al., 2008). 
The metabolic memory has also been shown to be present in type 2 
diabetes. Data from the follow-up of the United Kingdom Prospective Diabetes 
Study (UKPDS) have shown that type 2 diabetic patients, like type 1 diabetic 
patients in the DCCT-EDIC, who were on the standard treatment regimen during 
the study still have a higher incidence of microvascular and cardiovascular 
complications compared with their counterparts receiving intensive therapy 
throughout the trial and the follow-up period (Holman et al., 2008). This suggests 








3.1 Generation of irreversible biochemical response from a 
transient stimulus  
 
Sustained cellular responses to a transient stimulus are features of many 
biologic systems. An instructive example relevant to the major problem being 
addressed by this proposal is the differentiation of xenopus ooctyes after a brief 
exposure to progesterone (Schmitt and Nebreda, 2002). An important conceptual 
breakthrough was based on the observation that two progesterone-activated 
kinases - Cdc2 and MAPK - activate themselves, but also activate each other. 
However, since the phosphorylation events involved are rapid and reversible, 
simply knowing that positive feedback of kinase activity was involved in 
progesterone-induced oocyte differentiation did not did by itself explain how 
oocytes stably maintain the differentiated phenotype - with persistently activated 
kinases Cdc2 and MAPK - in the absence of progesterone. 
Theoretical modeling studies by Ferrell and Xiong predicted that the positive 
feedback features involving the two kinases could maintain a stable biochemical 
phenotype in differentiated oocytes (Xiong and Ferrell, Jr., 2003). This model 
predicted that inhibiting the positive feedback loops would cause a mature egg to 
dedifferentiate, adopting the phenotype of the immature oocyte. Using three 
different experimental methods to inhibit the positive feedback between MAPK and 
a protein upstream of MAPK – Mos - changed the activation of the two kinases 
after brief progesterone exposure from sustained to transient. The oocyte bistable 
switch-like response is showed schematically in figure 3.1. 
 
 
Figure 3.1 Bistable switch-like response based on positive feedback regulates xenopus oocyte 
differentiation in response to transient progesterone exposure. From (Xiong and Ferrell, Jr., 2003).  
 
A similar role for bistable switch-like responses based on positive feedback 
has been found for the differentiation and dedifferentiation of human embryonic 
stem (ES) cells. The transcription factors OCT4, SOX2, and NANOG were 
identified as critical determinants of ES cell differentiation by genome-wide 
transcriptional studies (Xiong and Ferrell, Jr., 2003). In the same way that critical 
kinases regulate the switch to differentiated xenopus oocytes, these transcription 
factors switch ES cells from undifferentiated to differentiated by means of positive 
feedback loops, and transient delivery of four such reprogramming transcription 
factors can also dedifferentiate human differentiated cells to cells similar to human 
!
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embryonic stem cells (Boyer et al., 2005). In general, bistable switch-like responses 
occur when there is a functional element in the regulatory network that exhibits a 
threshold-like response to a stimulus (Burrill and Silver, 2010). This characteristic 
can be quantitatively described by a Hill function in which the Hill coefficient is high. 
As illustrated in Figure 3.2, a smaller Hill coefficient (the exponent n) gives a 
graded response to increasing concentrations of X (n=1 in the figure). In contrast, a 
larger Hill coefficient results in a bistable, switch-like response (n=4 in the figure).  
 
 
Figure 3.2 Gene Circuits for Cellular Memory (A) Dynamics of regulated gene circuits described by Hill 
functions. (Left) The concentration of product Y is plotted as a function of the concentration of activator 
X, as described by Hill functions with n = 1, 2, and 4. β is the maximal expression level from Y's 
promoter when X is bound, and K defines the concentration of X needed to reach the threshold 
activation of Y. (Right) The concentration of product Y is plotted as a function of the concentration of 
repressor X, as described by Hill functions with n = 1, 2, and 4. β is the maximal expression level from 
Y's promoter when X is unbound, and K defines the concentration of X needed to reach the threshold 
for repression of Y.(B) Network motifs that achieve biological memory (Burrill and Silver, 2010).  
 
This concept is a critical feature underlying the switch of cell phenotype from 
one stable state to another. The underlying molecular components of these 
regulatory systems may be signaling molecules, silencing methylation modifications 
of histones, transcription factors, and metabolic reactions (Loh et al., 2006). With 
transcription factors, a stimulus can cause a single transcription factor to self-
activate, or cause two transcription factors to regulate each other, producing either 
two negative or two positive feedback interactions. Each can trigger a switch 
between two steady states when a threshold concentration of the activator or 
repressor protein is reached. 
 
Bistable feedback loop networks: sustained biological 
response after transient exposure to threshold level of 
activators or repressors
Burill, D.R., and Silver, P.A. Cell 140, 2010 !
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4.1 Materials  
 
Human aortic endothelial cells (HAEC) were obtained from Invitorgen (Grand 
Island NY). EGM2 Media plus growth factor additives were obtained from Lonza, 
(Walkerville, Md). 
PP2A inhibitor, okadiac acid, deferoxamine mesylate, and GSK-3β activity assay kit 
were from Sigma-Aldrich (St Louis ,Mo). [γ32P] ATP was from GE Health Care Life 
Sciences (Piscataway, N.J.). CM-H2DCFDA and JC-1 were from Invitrogen (Grand 
Island NY). Protein A agarose was from Roche (Nutley, NJ). AKT activity assay kit 
was obtained from Cell Signaling Technology (Danvers, MA). GSK3-β inhibitory 
peptide Myr-NGKEAPPAPPQSPP was obtained from EMD (San Diago CA). 
Antibodies to GSK3 β, p-GSK3-β (S9) were obtained from Cell Signaling 
Technology (Danvers, MA) and BD Bioscience (San Diego,Calif). Antibodies to 
Hexokinase II and to VDAC were obtained from Santa Cruz Biotechnology (Santa 
Cruz, Calif). Secondary antibodies for western blot and immunoprecipitation-WB 
were obtained from Invitrogen (Grand Island NY) and Sigma-Aldrich (St Louis, 
MO). PP2A Activity assay kit was bought from R&D Systems (Minneapolis MN). 
EPR tube for free iron measurement was bought from wilmad-lab glass (Vineland 
NJ). Mn-SOD, empty vector and Catalase adenovirus were obtained as previously 
described (D'Apolito et al., 2010). Constitutively active GSK-3β  adenovirus and 
plasmids with the cDNA of constitutively activated Akt1 (Akt-1CA), and dominant 
negative Akt (Akt-DN) were a kind gift of Dr Birnbaum. Akt-1CA, Akt-DN cDNAs 
were subcloned in a shuttle vector for adenoviral particle packaging.  
 
4.2 Cell Culture conditions  
 
Confluent HAECs (passage 1-4) were maintained in EGM2 media containing 
0.4% FBS plus growth factor additives. Cells were incubated for varying times with 
either 5 mM glucose, 25 mM glucose, with or without various inhibitors and target 
genes over expression: GSK-3β inhibitory peptide (10mM), PP2A inhibitors 
(okadiac acid and microcystin-LR, 100 nM and 500 mM respectively), deferoxamine 
(100mM). Mn-SOD, constitutively activated Akt, Akt-DN and GSK-3β  were used at 
an MOI of 100.  The cells were infected with viruses with the target genes 24 hours 
prior to high glucose treatment. 
 
4.3 Reactive oxygen species quantization 
 
 Cells were plated in 96-well cell culture plates. Intracellular reactive oxygen 
species were detected using the fluorescent probe CM-H2DCFDA. Cells were 
loaded with 10 µM CM-H2DCFDA after 2 times wash with non-phenol red MEM 
medium, incubated for 45 min at 37 °C, and analyzed with an HTS 7000 Bio Assay 
Fluorescent Plate Reader (Perkin Elmer) using the HTSoft program.  
 




4.4 Mitochondrial membrane potential 
 
Mitochondrial membrane potential was assessed using the dual emission 
potentiometric dye, JC-1 from Life Technologies. JC-1 aggregates fluoresce red (
597 nm), while monomers fluoresce green ( 539 nm). Briefly, after indicated 
treatment cells were stained with 1µM JC-1 for 20’ at 37 °C. Pictures were taken 
using an IX51 inverted microscope (Olympus America Inc.).  
Image merge was performed with the public domain software ImageJ (NIH; 
http://rsb.info.nih.gov/ij). 
 
4.5 Immunoprecipitation and Western blotting  
 
Immunoprecipitated proteins electrophoresed on 10% PAGE gels were 
transferred onto nitrocellulose membranes. The immunoblots were developed with 
1:1000 dilutions of primary antibody and anti-RABBIT IRDye™ 800CW (green) and 
anti-MOUSE (or goat) ALEXA680 (red). Membranes were scanned and quantitated 
by the ODYSSEY Infrared Imaging System (LICOR, NE).  
 
4.6 Determination of GSK-3β activity 
 
GSK-3β activity was measured using a kit from Sigma-Aldrich following the 
instruction of manufacture. In brief, cells were washed in cold PBS twice and lysed 
in 500 µl of lysis buffer and then scraped off and centrifuged (13000 g, 5min, 4°C). 
Protein was quantitated by the Bradford method. 200mg of cell lysate was added to 
the EZview Red Protein G Affinity Gel Equilibration of beads, which should be well 
equilibrated before use according the manufacture’s instruction, and rotated 
overnight at 4°C. Two negative control samples (Negative Control 1-no substrate 
and Negative Control 2-no antibody) should be prepared at the same time. 
Manufacturer’s assay procedure was followed accordingly. 
 
4.7 Determination of Akt1 activity   
 
Cells were washed in cold PBS 1X and lysed in 300 µl of lysis buffer (137 
mM NaCl, 20 mM Tris-HCL pH7.5, 1 mM MgCl2, 1 mM CaCl2, 10% glycerol, 1% 
NP40, protease inhibitors tablet (Roche), phosphatase inhibitors cocktail 1+2, 
100mM NaF, 10mM Na-Pyrophosphate, 1 mM microcystein). Cells were rocked at 
4°C for 20 min, and then scraped off and centrifuged (13000 g, 5mn, 4°C). Proteins 
were quantitated by the Bradford method. Akt activity was measured following the 
instruction of the ELISA kit from Cell Signaling Technology. 
 
4.8 Determine of PP2A Activity 
 
PP2A activity was analyzed using a kit form R&D System. The HAECs were 
cultured until confluent in 10mm dish. After washed with ice-cold PBS twice, the 
cells were lysed with lysis buffer. Enzyme activity measurement was then 
performed following the manufacturer’s instructions. 
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4.9 Determination of intracellular free iron 
 
EPR Sample Preparation 
The HAECs (106/sample) were scraped in PBS and spun down at 1,000 x g for 10 
min. The cell pellet was resuspended in 1ml of PBS to wash. The cell pellet was 
resuspended in 200 µl of assay buffer, 20 mm Tris-Cl, pH 7.4, 10% glycerol and 
2mM deferoxamine mesylate.  Exactly 200µl of this sample was transferred into an 
EPR tube, and the sample was frozen on dry ice or liquid nitrogen immediately and 
stored at –70°C until EPR measurements were performed.  
High spin mononuclear ferric iron (electron spin S = 5/2) chelated in a 
rhombic environment gives rise to a characteristic EPR spectrum dominated by a 
peak at apparent g-value (g’) equal to approximately 4.3. This signal has been 
referred to as “free” or “garbage” iron because it often originates from non-
specifically bound iron or iron released upon the denaturization of protein active 
sites. The free iron EPR spectrum is distinct from that obtained from iron bound to 
heme or present in iron-sulfur clusters. In the this study, the g’=4.3 signal is used to 
monitor the concentration of free iron present in primary human aortic endothelial 
cells upon treatment with high glucose and Mn-SOD over expression.   In the cell, 
free iron can be in both the high spin ferrous (Fe2+) and ferric (Fe3+) states.   High 
spin Fe2+ is an S=2 paramagnetic species that is typically not detectable at the 
temperatures and EPR frequencies employed in this study.  In order to make it 
EPR-detectable, the ferrous species is converted to high spin ferric by treatment 
with deferoxamine mesylate (DF) which binds to Fe2+, lowers its redox potential and 
allows molecular oxygen to oxidize it to Fe3+. The relative amount of the DF:Fe3+ 
complex can then be determined by measuring the amplitude of the g’=4.3 EPR 
peak.   More quantitative determination of iron concentration can be done using 
procedures employing S = 5/2 Fe or S = ½ Cu2+ or Vo2+ standards.  
Experimental section   
EPR spectra were registered on a Varian E-line 112 X-band spectrometer 
equipped with a rectangular TE102 resonator.  A liquid nitrogen finger dewar was 
inserted into the resonator to keep the sample at 77K during the measurement.  
Typical spectral acquisitions parameters were as follows.   EPR frequency:  9.11 
GHz; power:  20 mW;  modulation amplitude: 20 G; time constant: 0.5 seconds; 
scan time: 2 minutes; number of scans averaged: 4 – 9. Spin concentrations were 
estimated by comparing the amplitude of the g’=4.3 signal with spectra obtained 
from standards of known concentrations of DF:Fe3+ in buffer solution 
(Woodmansee and Imlay, 2002). 
 
4.10 Chromatin Immunoprecipitation Experiments 
 
ChIP experiments were performed as previous described (Milne et al., 2009). 
Antibodies to unmodified H3 (catalog# ab1791) and to Histone H3 mono methyl K4 
(catalog# ab8895) are from Abcam. Results were quantified comparing input vs. IP 









4.11 Statistics  
 
Data were analyzed using one-factor ANOVA to compare the means of all the 
groups. The Tukey–Kramer multiple comparisons procedure was used to determine 
which pairs of means were different. 
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5.1 Transient High Glucose causes sustained ROS production 
 
A previous study by Brownlee et al. shows that transient hyperglycemia induced 
persistent epigenetic changes in the promoter of the NF-κB p65 subunit in both 
Human Aortic Endothelial Cells (HAECs) and in non-diabetic mice. In the proximal 
promoter region of p65, the increased monomethylation of histone 3 lysine 4 
(H3K4me1) by the histone methyltransferase Set7 caused a sustained increase in 
p65 mRNA, leading to a sustained increase in expression of the proatherogenic 
NF-kB–responsive genes MCP-1 and VCAM-1. Both the persistent epigenetic 
changes and the increased inflammatory gene expression, induced by transient 
hyperglycemia, were prevented by reducing mitochondrial superoxide production 
(El Osta et al., 2008). Since in normal cells these epigenetic changes were rapidly 
reversed by histone demethylases and histone methyltransferases (Wysocka et al., 
2005) we hypothesized that epigenetic changes remain after transient 





















Figure 5.1 Impact of transient high glucose on Histone methylation and p65 expression. (A) Time 
course of ChIP H3K4me1 after transient hyperglycemia in HAECs. (B) NF-kB p65 subunit mRNA levels 
after transient hyperglycemia. (C) MCP-1 VCAM-1 mRNA expression after transient hyperglycemia. 
Control cells were maintained at 5 mM glucose. Data are the mean ± S.E.M from 5 independent 
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We performed a chromatin immunoprecipitation (ChIP) time course to define when 
the monomethylation in histone 3 lysine 4 occurred in HAECs. A significant 
increase occurred after 6 and 16 hours of high glucose and remained at 
comparable levels after 3 days of low glucose (Fig. 5.1.A). As demonstrated in the 
precedent paper (El Osta et al., 2008) the increased H3K4me1 caused an increase 
in p65 mRNA and a subsequent augmentation of MCP-1 and VDAC-1 mRNA levels 
(Fig. 5.1.B-C). 
6 hours Glucose exposure induce a X fold increase in ROS production in HAEC. 
This increase was still present after 2 days of normal glucose. This increase was 
prevented by overexpression of manganese superoxide dismutase (MnSOD) 
(Brownlee, 2001) demonstrating that transient high glucose induces an increase in 
mitochondrial ROS production (Fig. 5.2). 
 
 
Figure 5.2 Impact of glucose levels on ROS levels. ROS levels measured by 2’,7’-dichlorfluorescein-
diacetate (DCFH-DA) in HAECs exposed to 25 mM glucose at the indicated time. Cells at 5 mM glucose 
were used as control. Data are the mean ± S.E.M from n independent experiments. * p<0.01. 
 
High glucose exposure induce a rapid increase in ROS production, reaching a 
maximum after 1 hour and staying at the same levels up to 6h (Fig. 5.3.A). To 
better understand the time of high glucose exposure able to cause the 
augmentation of ROS levels in cells subsequently exposed to normal glucose 
condition, ROS levels were measured in cells transiently exposed to high glucose 
(25 mM) for different intervals of time and then returned for 2 days in physiological 
glucose concentration (5 mM). Figure 5.3.B shows that there was no significant 
increase of ROS levels compared with the control (HAECs in 5 mM glucose for 3 
days) when the high-glucose treatment did not exceed the 4h. Conversely, the 
levels of ROS were still significantly higher after two days in 5 mM glucose, when 

















Figure 5.3 Time course of ROS production measured by DCFH-DA. (A) HAECs were exposed to 
25mM glucose at the indicated intervals. Cells exposed at 5mM glucose were considered as control. (B) 
HAECs were exposed to 25 mM glucose at the indicated interval and then returned to 5mM glucose for 
2 days. Cells maintained at 5mM glucose were considered as control. Data are the mean ± S.E.M from 
5 independent experiments. * p<0.01. 
 
Our data showed post-hyperglycemia persistent high levels of ROS. The 
continuous ROS production, in normal glucose level, highlights a modification in 
mitochondria physiology as demonstrated by the experiment in Figure 5.4. HAECs 
were pretreated for 6h in high glucose (25 mM) plus two days in low glucose (5 
mM) and then treated for 6h with different glucose concentration from 0 to 25 mM 
(Fig. 5.4, diagram-A). Cells maintained in 5 mM glucose and then treated with 
different concentration of glucose (Fig. 5.4, diagram–B) were used as control. 
Figure 5.4 shows the ROS levels as function of the glucose concentration of the 
second treatment (represented by the X treatment in the upper diagram). The 
control cells (B condition-blu line) required 10 mM glucose at least to increase the 
ROS levels, whereas the cells pre-treated with high glucose (A condition-red line) 
had higher levels of ROS even in glucose concentration below 5 mM. This resulted 
in a shift to the left of the glucose concentration ROS curve. 
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Figure 5.4 ROS levels in HAECs with different glucose pretreatment. HAECs pretreated for 6h in 25 
mM glucose followed 2 days in 5 mM glucose (red line) and HAECs treated as control with 5 mM 
glucose (blue line). Then the cells were treated for 6h at the indicated glucose concentration (from 0 to 
25mM with a 0.5 mM increase per experimental point). Data are the mean ± S.E.M from 5 independent 
experiments. * p<0.01.  




5.2 Sustained increase in mitochondrial ROS production is 
maintained by a multi-component positive feedback loop 
 
Based on the previous observations we hypothesized that the sustained increase of 
mitochondrial ROS by transient hyperglycemia is based on a feedback loop that 
changes the mitochondria proprieties. Our aim was to identify the critical regulatory 
network that shifts vascular endothelial cells to a state of persistent ROS production 
after transient exposure to high glucose. 
The physiological rate of mitochondrial ROS production is inversely proportional to 
the availability of cytosolic ADP (Cadenas and Davies, 2000). Thus, low ADP levels 
induce an increase in the magnitude of the mitochondrial membrane potential (ΔΨ), 
which, in turn, decreases the respiratory rate, leading to the stimulation of ROS 
generation. In fact, mitochondrial ROS generation is strongly dependent on ΔΨ 
levels, because high H+ gradients increase O2- and H2O2 formation (Korshunov et 
al., 1997). Hexokinase II (HKII) activity is critical for sustaining a constant ADP 
steady-state cycling which sets ΔΨ down to lower levels and, consequently, 
decreases the mitochondrial ROS formation in rat brain cells (da Silva et al., 2004). 
HKII binds the outer mitochondrial membrane (OMM) interacting with the voltage-
dependent anion channel (VDAC) and regulating the exchange of metabolites into 
and out the mitochondria (Pastorino et al., 2002). 
In our system we hypothesized that there was a dissociation of HKII from VDAC-1 
with a consequent impaired ATP/ADP ratio. In order to prove this correlation we 
induced HKII detachment from VDAC-1 by using a peptide formed by the N-
terminal 15 amino acids of HKII linked to a HIV-1 TAT sequence to allow its entry 
into the cell (Chiara et al., 2008).  
 
 
Figure 5.5 Impact of TAT-HK on ΔΨ  and ROS production. HAECs were treated with TAT-HK 1 µM 
for 1 hour in 5 mM glucose medium. The TAT-Scr was used as control. In the upper panel: Mitochondrial 
membrane potential measured by JC-1 probe. In the lower panel ROS production measured by DCFH-
DC. Data are the mean ± S.E.M from 5 independent experiments. * p<0.01. 
 
Treatment with 1µM of TAT-HK for 1 h induced an increase in mitochondrial 
membrane potential as showed in the upper level of Figure 5.5. The cells were 
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stained with JC-1 and the high potential promoted the formation of dye aggregates 
(red color). TAT-Scr was used as negative control. HKII detachment was also able 
to induce high levels of ROS in cells grown in 5 mM glucose (Fig. 5.5 lower panel). 
Thus we evaluated, by immunoprecipitation, the VDAC-HKII association as function 
of the time of high-glucose exposure. Figure 5.6.A shows that the dissociation of 
HKII from VDAC-1 occurred after 3h of high glucose treatment. Moreover, the 
dissociation persisted even when glucose levels returned to 5 mM concentration. 
GSK3β mediates VDAC-HKII dissociation through threonine 51 phosphorylation 
(Pastorino et al., 2005a). Figure 5.6.B shows that GSK-3β inhibitor prevented the 
phosphorylation threonine 51 and, subsequently, the dissociation of HKII from 
VDAC-1. A time course of VDAC-1 phosphorylation proved that phosphorylation 
started at 3 hours of high glucose treatment and was persistent after 6 hours of 






Figure 5.6 High glucose effect on VDAC-HKII association. Immunoprecipitation blotting of HAECs 
treated with 25 mM glucose at different time. (A) VDAC-HKII association. (B) VDAC threonine 
phosphorylation. Pre-treatment with GSK-3β inhibitor (10µM) for 3 hours prevents VDAC 
phosphorylation and as a consequence VDAC-HKII dissociation. Data are the mean ± S.E.M from 5 
independent experiments. * p<0.01. 




Activation of GSK-3β is associated with mitochondrial dysfunction and cellular 
injury (Murphy, 2004; Morrison et al., 2002); we found an up-regulation of GSK-3β 
activity after 3 hours of high glucose treatment. This upregulation reached a stable 
maximum level at 6 hours (Figure 5.7). Moreover, when HAECs were returned to 5 
mM glucose medium after 6 hours exposure to high glucose, the increased GSK-3β 
activity persisted unchanged for at least 2 days of normal glucose levels. It is well 
known that GSK-3β can be inactivated by Akt-1, through the phosphorylation of the 
single serine residue serine 9, located in the regulatory N-terminal domain (Frame 
and Cohen, 2001). Indeed, prior overexpression of Akt-1, by adenoviral infection, 




Figure 5.7 Time course of GSK-3β  activity measured as 32P incorporated in a substrate. Akt-1 
adenoviral infection (100 MOI) prevented hyper-activation of GSK-3β in high glucose condition. No effect 
with empty vector used as a control (data not showed). Data are the mean ± S.E.M from 5 independent 
experiments. * p<0.01. 
 
Having demonstrated that the overexpression of Akt-1 by adenoviral infection 
prevented GSK-3β induction, Akt-1 function has been evaluated in our condition. 
As showed in Figure 5.8 the activity started to decrease significantly after 3 h of 
high glucose. The decreased activity was persistent even after 2 days of low 
glucose levels after transient exposure for 6 hours to high glucose medium. 
Because Akt-1 activity is known to be negatively regulated by the protein 
phosphatase 2A (PP2A) (Millward et al., 1999), HAECs were pretreated with the 
PP2A inhibitors, Okadaic Acid (OKA) and Microcystin-LR (Mic). Figure 5.8 shows 
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Figure 5.8 Time course of Akt-1 activity. Akt-1 activity measured by ELISA assay. PP2A inhibitor 
Microcystin-LR (500µm) and Okadaic Acid (100nM) prevented Akt-1 decrease activity in High Glucose 
condition. Data are the mean ± S.E.M from 5 independent experiments. * p<0.01. 
 
Decreased Akt-1 activity is caused by dephosphorylation of Thr 308 by PP2A 
(Millward et al., 1999). A time course proved a time-depend increase in PP2A 
activity since 2 h of high glucose treatment reaching a maximum at 6 hours. 
Remarkably, this increase in PP2A activity persisted during subsequent 2 days in 
normal glycemia. PP2A hyperactivity was completely prevented inhibiting 
hyperglycemia-induced ROS by overexpressing MnSOD and Catalase and by 




Figure 5.9 Time course of PP2A activity measured by immunoprecipitation assay kit. Adenoviral 
overexpression of MnSOD, catalase (100 MOI) and desferoxamine (DFO 100 mM) prevent PP2A hyper-











Iron–sulphur (FeS) clusters are ROS-sensitive components of many (>120) cellular 
proteins, like proteins involved in electron transfer. Oxidation of FeS causes loss of 
protein function with releases of free Fe, which may participate in Fenton reaction 
(Kuo et al., 2008). The Fenton reaction forms hydroxyl radical from hydrogen 
peroxide in the presence of ferrous ions (Raha and Robinson, 2000): 
 H2O2 + Fe2+ → OH- + OH•+ Fe3+    
PP2A has been showed to be ROS sensitive with controversial effects on its 
activity (Cicchillitti et al., 2003; Chen et al., 2009). In our system hydroxyl radicals 
were able to incresase PP2A (Fig. 5.9). 
Since we found a decrease in PP2A activity after treatment with Desferoxamine, we 
performed an experiment to quantify free iron by electron paramagnetic 
spectroscopy (EPR). 
In our system after 2 hours of high glucose there was an increase in cellular free 
iron. This was prevented by the overexpression of MnSOD demonstrating that 




Figure 5.10 Time course of Free Iron. Intracellular Free measured by Electron Paramagnetic 
Spectroscopy (EPR). Adenoviral overexpression of MnSOD, (100 MOI) prevents Iron release. Data are 
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5.3 Phenocopying loop activation 
 
In order to confirm the involvement of the principal component of the loop identified 
in our system, we did an experiment with the adenoviral vector expressing for Akt-1 
dominant negative (Akt-DN) and GSK-3β constitutively active (GSK-3β-CA). As 
previously described, cells were stained with JC-1 to evaluate the promotion of dye 
aggregates (red) by the high membrane potential. Figure 5.11 (upper panel) shows 
that cells grown in 5 mM glucose and infected with the Akt-DN or GSK-3β-CA 
adenoviral vectors had a higher membrane potential compared with non-infected 
cells grown in 5 mM glucose. It can also be seen that these infected cells had a 
similar membrane potential to non-infected cells exposed to 25 mM glucose for 6 
hours.  
Analogously, Figure 5.11 (lower panel) shows that the infected cells had 




Figure 5.11 Phenocopy loop activation by adenoviral infection of Akt-1 dominant negative and 
GSK-3β  costitutively active. Akt-DN and GSK-β-CA infected cells were grown in 5 mM glucose. Non-
infected cells were grown either in 5mM or 25 mM glucose. Cells empy vector infected (mock) were 
grown in 5 mM glucose. Upper panel: Mitochondrial membrane potential measured by JC-1 probe. 
Lower panel:  ROS levels measured by DCFH-DC. Data are the mean ± S.E.M from 5 independent 
















5.4 Disruption of feedback loop components reverses the 
sustained effects of transient glucose stimulus 
 
We identified a multi-component positive feedback loop induced by transient 
exposure to high glucose. The activation of this loop maintains persistently high 
ROS levels even when the cells were returned to normal glucose conditions. This 
results in the shift to the left of the glucose concentration-ROS generating curve in 
mitochondria. 
HAECs were treated as indicated in the diagrams below. Figure 5.12 shows ROS 
levels as function of the glucose concentration of the second treatment 
(represented by the X treatment in the upper diagram). As shown before in Figure 
5.4, the control cells (B condition-blu line) required 10 mM glucose, at least, to 
significantly increase the ROS levels, whereas the cells pre-treated with high 
glucose (A condition-red line) had higher levels of ROS even in glucose 
concentration below 5 mM. This resulted in a shift to the left of the glucose 
concentration ROS curve. Cells pretreated for 6h in high glucose (25 mM) plus two 
days in low glucose (5 mM) and then treated for 6h with different glucose 
concentration from 0 to 25 mM but in presence of a GSK-3β inhibitor (gold curve) 
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Figure 5.12 GSK-3β  inhibitor reverted ROS. ROS production in HAECs pretreated for 6h in 25 mM 
glucose followed 2 days in 5 mM glucose (red line) and HAECs treated as control with 5 mM glucose 
(blue line). After these conditions, cells were treated for 6h with different glucose concentration (from 0 





























Transient exposure to high glucose induces methylation of histones associated with 
the p65 promoter. Histone methylation is an important post-translational 
modification involved in fundamental processes such as transcriptional regulation 
and genome stability (Chen et al., 2009; Martin and Zhang, 2005). In particular, 
methylation of H3K4 (lysine 4 of histone 3) favors transcriptional activation (Kondo 
et al., 2003). To confirm the involvement of each single loop component in histone 
methylation we performed a ChIP assay for H3K4me1. HAECs were transient 
exposed to high glucose and then treated to perturb any of the elements in the 
feedback loop. The result was a complete restored system to its normal state, 




Figure 5.13 Transient normalization of loop components reversed H3K4me1. NF-κB p65 promoter 
H3K4me1 after transient hyperglycemia in HAECs. Data are the mean ± S.E.M from 5 independent 
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The disruption of the feedback loop by acting on the loop components was able to 
revert the H3K4me1 increase in p65 proximal promoter and to revert the increase 





Figure 5.14 Transient normalization of MnSOD, Akt-1 and GSK-3β  reversed p65 mRNA and gene 
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In the present study we found how transient hyperglycemia induced the long-
lasting activating epigenetic changes in the proximal promoter of the NF-κB subunit 
p65. Since in normal cells the epigenetic changes described are rapidly reversed 
by histone demethylases and methyltransferases we discovered how transient 
spikes of hyperglycemia cause persistent mitochondrial overproduction of reactive 
oxygen species (ROS), during subsequent periods of prolonged normal glucose, 
causing persistent epigenetic changes in the promoter of p65. We identified a multi-
component positive feedback loop induced by transient exposure to high glucose, 
in human vascular endothelial cells, which maintains persistently increased ROS 
production in normal glucose condition by shifting the glucose concentration-ROS 
generating curve of mitochondria to the left (Figure 5.4). Transient disruption of any 
of the elements in the feedback loop rapidly restores the system to its normal state, 
including reversing persistent increase in ROS production, persistent epigenetic 
changes and persistent increase NF-κB-dependent pro inflammatory gene 
expression. 
 
Our observations of metabolic memory are based on behavior of many 
biologic systems where sustained cellular responses can be seen after transient 
stimulus and are maintained by the continuous activation of feedback loops. These 
feedback loops function as bistable, hysteretic toggle switches. The term “bistable” 
means that the system can be in either of two alternative stable steady states, 
depending upon its history, and the term “hysteretic” means that once the system 
has been switched from one state to the other, it tends to stay there.  
Long-lasting stress, even when glucose level is normalized, has been 
reported in various contexts, but the molecular mechanisms remain unknown (Ihnat 
et al., 2007; Paneni et al., 2012; Ceriello et al., 2007). In our work for the fist time 
we show the molecular mechanism underlying the sustained ROS production. 
Overproduction of ROS by mitochondria is considered as a causal link between 
elevated glucose and the major biochemical pathways involved in the development 
of vascular complications in diabetes (Nishikawa et al., 2000). Moreover 
hyperglycemia-induced ROS formation causes the epigenetic changes found in the 
promoter of the NF-κB p65 subunit in both cultured human aortic endothelial cells 
and in non-diabetic mice (El Osta et al., 2008). 
The epigenetic modifications allow cells/organisms to quickly respond to changing 
environmental stimuli, (Gluckman et al., 2007; Bjornsson et al., 2004; Whitelaw and 
Whitelaw, 2008) and also confer the ability for the cell to “memorize” these 
encounters once the stimulus is removed (Dolinoy and Jirtle, 2008; Morgan and 
Whitelaw, 2008).  
Here we used transient hyperglycemia as a model to study persistent ROS 
generation and epigenetic changes caused by shift from one bistable state of 
system to another.  




Our investigation was focused on the role of mitochondria in metabolic 
memory. Mitochondria are not static structure in the cell and are the major source 
of hyperglycemia-induced ROS (Nishikawa et al., 2000). Here we report how 
transient high glucose can dramatically change mitochondrial proprieties as 
showed by the ROS production curve shifted to the left even in glucose 
concentration lower than 5 mM (Figure 5.4).  
Our data show that 2 hours high glucose exposure causes ROS production 
leading to oxidation of sensitive iron-sulphur (FeS) clusters (Rouault and Klausner, 
1996), the major components of mitochondrial respiratory electron transport chain, 
resulting in loss of protein function and, at the same time, releasing of free iron. 
The superoxide produced by electrons transport chain is converted by 
superoxide dismutase (MnSOD) in H2O2, which reacts with free iron in Fenton 
catalysis, generating hydroxyl radicals (Raha and Robinson, 2000). 
The diagram in figure 6.1 shows the normal and high glucose conditions. 
 
 
Figure 6.1 Schematic representation of ROS production in normal and high glucose conditions. 
 
PP2A is one of the main intracellular serine/threonine phosphatase and plays 
important roles in maintaining endothelial cell physiological functions, including 
regulation of endothelial cell cytoskeletal structure, protection of the endothelial cell 
barrier, regulation of glucose metabolism and fat synthesis, and regulation of 
endothelial nitric oxide synthase phosphorylation status (Kabashima et al., 2003; 
Palanivel et al., 2004; Tar et al., 2006; Urbich et al., 2002; Zolnierowicz, 2000). 
PP2A has been showed to be ROS sensitive with controversial effects (Cicchillitti et 
al., 2003; Chen et al., 2009), however our results show that the hydroxyl radicals 
generated by Fenton reaction are able to increase PP2A activity as demonstrated 
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by overexpression of MnSOD, Catalase and employment of the iron chelator DFO 
which are all able to prevent increased PP2A activity. It is well known that PP2A 
controls negatively Akt-1 by dephosphorylation in Thr 308 (Seeling et al., 1999), 
and through this effect, PP2A is a physiologic negative regulator of insulin's 
metabolic signaling pathway (Ugi et al., 2004). As a result of PP2A over-activation 
we found a significant decrease in Akt-1 activity since 3 hours of high glucose 
treatment. Akt-1 has been shown to regulate hexokinase expression, activity, and 
mitochondrial interaction (Miyamoto et al., 2008; Aubert-Foucher et al., 1984; 
Vander Heiden et al., 2001) also through GSK-3β inhibition by dephosphorilation in 
serine 9 (Cross et al., 1995). The binding of HKs to the mitochondria may be 
dependent on the phosphorylation state of VDAC. Pastorino et al. demonstrated 
that GSK-3β can phosphorylate VDAC affecting HK binding to the mitochondria 
(Pastorino et al., 2005b). We found an increase in GSK-3β activity, due to Akt-1 
inhibition, that lead to VDAC phosphorylation and as a consequence to VDAC-HK 
dissociation after 3 hours of high glucose treatment, furthermore VDAC-HK 
dissociation is persistent in normal glycemia after transient high glucose stimulus. It 
has been very well established that HKII activity is critical to set down ∆Ψ and 
moreover mitochondrial high ∆Ψ is associated with ROS formation (Raha and 
Robinson, 2000; da Silva et al., 2004; Korshunov et al., 1997). Thus, the persistent 
ROS production we found in normal glucose is due to VDAC-HK dissociation that 
causes increase in mitochondrial ∆Ψ leading to continuous ROS production. The 
use of a peptide, formed by N-terminal 15 aminoacids of HKII linked to a HIV-1 TAT 
sequence, was able to dissociate VDAC-HKII in 5 mM glucose causing ∆Ψ 
increase and ROS production confirming the involvement of VDAC-HKII in the 
continuous ROS formation in our system.  
Our findings suppose the presence of a critical component that actives the loop to 
have ROS production in memory condition, indeed ROS formation turns up after 4 
hours of transient high glucose treatment, persisting unchanged for two days in low 
glucose. After at least 4 hours of transient high glucose treatment, there is a “critical 
switch” turned on able to allow ROS production in low glucose conditions. It is 
difficult to identify the nodal control of the switch, but it is necessary the dissociation 
of HK from VDAC so that we can have persistent ROS production. The diagram in 
figure 6.2 shows a schematic representation of the feedback loop. 
 





Figure 6.2 Schematic representation of feedback loop.  
 
The most interesting part of our work was the possibility to act on the loop 
component and revert the damaging effects of transient high glucose stimulus. We 
were able to reset GSK-3β activity using a small peptide inhibitor resulting in ROS 
normalization as proved by the experiment in figure 5.12 (Chapter 5). The cells 
transient exposed to high glucose for 6 hours plus two days in low glucose exhibit 
persistent ROS production even after treatment with glucose concentration below 5 
mM glucose. The treatment for 6 hours with GSK-3β inhibitor was able to restore 
the normal mitochondrial physiology represented by the curve comparable with the 
control. Following this, the persistent epigenetic changes induced by transient high 
glucose were completely reversed in these experiments normalizing each 
component of the feedback loop.  
Data from the EDIC study, which followed patients with type 1 diabetes after 
they completed the DCCT, show that early chronic exposure to a moderately high 
level of hyperglycemia has prolonged effects on diabetic complications during 
subsequent periods of improved glycemia, showing clinically the “metabolic 
memory.” For example, atherosclerotic changes not even present at the end of the 
DCCT appeared subsequently in the previously higher HbA1c group, followed by a 
two fold increase in myocardial infarction, strokes, and cardiovascular death. This 
occurred despite the fact that their HbA1c since the end of the DCCT was identical 
to that of the formerly intensive control group during the entire time that these 
arterial changes developed (Nathan D.M. et al., 2003; Nathan D.M., et al. 2005). 
The transient hyperglycemia causes persistent atherogenic effects during 
subsequent normoglycemia by inducing long-lasting changes in chromatin 
remodeling. These persistent changes in gene expression are induced by spikes of 
hyperglycemia that have durations too short (6-16 hours followed by 6 days of 
normal glycemia) to influence HbA1C values (El Osta et al., 2008). These results 
highlight the dramatic and durable effects that short-term hyperglycemic spikes can 
have on vascular cells and suggest that transient spikes of hyperglycemia may be 
an HbA1c-indipendent risk factor for diabetes complications. 
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Increasing understanding about the mechanisms underlying glycemic 
variability and its potential deleterious consequences, and determining how better 
to reduce the magnitude and frequency of glycemic spikes, should become near-
term priorities for translational and clinical type 1 diabetes research. Physicians will 
have to realize that much remains to be done in identifying important factors 
contributing to microvascular complications risk, which are not captured by the 
HbA1c. 
 In conclusion, our work introduce the identification of a mechanism that 
explain why microvascular complications progress also in presence of improved 
glycemic control and potentially may contribute in defining novel therapeutic target 
and additional markers for monitoring glycemic control and for designing better 
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